Next Article in Journal
WO3 Photocatalyst Containing Copper Inactivates SARS-CoV-2 Pango Lineage A and Omicron BA.2 Variant in Visible Light and in Darkness
Previous Article in Journal
A Recombinant Vaccine-like Strain of Lumpy Skin Disease Virus Causes Low-Level Infection of Cattle through Virus-Inoculated Feed
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pathogens
Volume 11
Issue 8
10.3390/pathogens11080921
pathogens-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Non-Endemic Leishmaniases Reported Globally in Humans between 2000 and 2021—A Comprehensive Review

by
Rafael Rocha
1,
André Pereira
2,3 and
Carla Maia
1,*
1
Global Health and Tropical Medicine (GHTM), Instituto de Higiene e Medicina Tropical (IHMT), Universidade NOVA de Lisboa, 1349-008 Lisbon, Portugal
2
Faculdade de Medicina Veterinária, Universidade Lusófona, 1749-024 Lisbon, Portugal
3
Escola Superior de Saúde, Proteção e Bem Estar Animal, Instituto Politécnico da Lusofonia, 1749-024 Lisbon, Portugal
*
Author to whom correspondence should be addressed.
Pathogens 2022, 11(8), 921; https://doi.org/10.3390/pathogens11080921
Submission received: 19 July 2022 / Revised: 9 August 2022 / Accepted: 12 August 2022 / Published: 16 August 2022
(This article belongs to the Section Parasitic Pathogens)
Browse Figures
Versions Notes

Abstract

:
Leishmaniases are human and animal parasitic diseases transmitted by phlebotomine sand flies. Globalization is an important driver of the burden and in the current dynamics of these diseases. A systematic review of articles published between 2000 and 2021 was conducted using the PubMed search engine to identify the epidemiology and clinical management of imported human leishmaniases as a fundamental step to better manage individual cases and traveler and migrant health from a global perspective. A total of 275 articles were selected, representing 10,341 human imported cases. Identified drivers of changing patterns in epidemiology include conflict and war, as well as host factors, such as immunosuppression, natural and iatrogenic. Leishmania species diversity associated with different clinical presentations implies diagnostic and treatment strategies often complex to select and apply, especially in non-endemic settings. Thus, diagnostic and management algorithms for medical clinical decision support are proposed. Increased surveillance of non-endemic cases, whether in vulnerable populations such as refugees/migrants and immunocompromised individuals or travelers, could improve individual health and mitigate the public health risk of introducing Leishmania species into new areas.

1. Introduction

Leishmaniases are a group of diseases caused by protozoa belonging to the genus Leishmania. The parasites are transmitted by phlebotomine sand flies, and the disease is zoonotic in most settings. Leishmaniases are worldwide distributed and can be separated geographically into Old World (OW) and New World (NW) diseases, with different species occurring in different areas [1]. Over 20 species have been recognized as human pathogens and clinical manifestations of leishmaniases vary largely but are often divided into two clinically distinct forms: visceral leishmaniasis (VL) and cutaneous leishmaniasis (CL). VL is caused by parasites of the Leishmania donovani complex (L. donovani in the Old World and L. infantum in both the Old and New Worlds) being responsible for causing a severe disease which is lethal when untreated. While L. donovani transmission is anthroponotic, the life cycle of L. infantum (synonym L. chagasi in NW) is mostly zoonotic, with domestic dogs as the main reservoirs of human infection. CL, caused by several species of Leishmania and responsible for considerable morbidity in endemic foci, ranges from a benign form with spontaneous resolution, to a disfiguring skin condition involving mucosal tissues [2]. According to [3], 98 countries and territories are endemic to leishmaniasis, with more than 12 million infected people, and with an estimated annual incidence of 50,000 to 90,000 VL cases and 600,000 to 1 million CL cases [4].
Reporting policies and practices in endemic countries are inconsistent, with a lack of systematic reporting of all human clinical forms of leishmaniases, leading to an underestimation of the local and global burden of leishmaniasis [5]. On the other hand, the available information shows an increase in the number of imported cases in endemic and non-endemic countries [6,7,8,9,10,11,12], which can be explained by a combination of factors, such as increased human traveling, migration, or population displacement from or to endemic areas and an increase in the number of susceptible populations due to immunosuppressive factors, co-morbidities, and aging. Altogether, increased human mobility and globalization have expanded the at-risk population for leishmaniasis and, simultaneously, pose a risk of geographic expansion of Leishmania species.
The present study aimed to summarize and analyze the epidemiology, clinical presentation, diagnosis, and management of non-endemic human leishmaniasis, through a comprehensive review of the literature in the last 22 years (2000–2021) to raise awareness of the medical community regarding the challenges associated with the diagnosis and management of this parasitic disease.

2. Search Strategy, Eligibility, and Review

A comprehensive literature search was performed on 12 November 2021 by sourcing National Library of Medicine (NLM) resources through PubMed (https://pubmed.ncbi.nlm.nih.gov/; accessed on 12 November 2021) using the following Boolean string: (“leish*”[All Fields] AND (“travel”[MeSH Terms] OR “travel”[All Fields] OR “trip”[All Fields] OR “trips”[All Fields] OR “traveling”[All Fields] OR “travelling”[All Fields] OR “travels”[All Fields] OR “traveled”[All Fields] OR “traveler”[All Fields] OR “traveler s”[All Fields] OR “travelers”[All Fields] OR “travelled”[All Fields] OR “traveller”[All Fields] OR “traveller s”[All Fields] OR “travellers”[All Fields] OR (“migrate”[All Fields] OR “migrated”[All Fields] OR “migrates”[All Fields] OR “migrating”[All Fields] OR “migration”[All Fields] OR “migrational”[All Fields] OR “migrant”[All Fields] OR “migrants”[All Fields] OR “migrations”[All Fields] OR “migrator”[All Fields] OR “migrators”[All Fields]) OR (“import”[All Fields] OR “importation”[All Fields] OR “importations”[All Fields] OR “imported”[All Fields] OR “importer”[All Fields] OR “importers”[All Fields] OR “importing”[All Fields] OR “imports”[All Fields]) OR (“refugee s”[All Fields] OR “refugees”[MeSH Terms] OR “refugees”[All Fields] OR “refugee”[All Fields])) AND (“human s”[All Fields] OR “humans”[MeSH Terms] OR “humans”[All Fields] OR “human”[All Fields]) OR “child*”[All Fields] OR “man”[All Fields] OR “woman”[All Fields] OR “patient”[All Fields] OR “patients”[All Fields]).
Search results were saved as a comma-separated value (CSV) file and imported into Microsoft Excel®. Study eligibility was manually assessed by two independent researchers in a blind manner. All records were screened according to the title, and abstract, if available. Only studies published between 2000 and 2021 were included, even if the cases reported were diagnosed in previous years. Only original research articles reporting humans with non-endemic Leishmania infection (i.e., reportedly infected by Leishmania parasites in a country different than the one they were living in at the moment of diagnosis) were retained, including those published in some languages other than English (Figure 1).
The presence of repeated cases in different articles was assessed—either confirmed, when explicitly mentioned in the text, or suspected, based on the authors, place of infection, year, and place of diagnosis (including hospital or center). Articles, where all or most cases reported, had (certainly or likely) been previously described in the literature were mostly discarded (except if they contained clinical or epidemiological details not published in previous works). This was the case for two GeoSentinel articles [13,14]. Articles, where some cases in a series had (certainly or likely) been previously described, were retained, but some cases were discarded, either entirely or in part of the information. This verification process of repeated cases was performed manually and for all the selected articles.
Some records had missing data, and the denominators mentioned in the text and tables count only those where data was available. Articles, where the place of infection included a list of several countries, were counted for the region of infection, but not for the country of infection. The same principle was applied to the place of diagnosis. Regions of infection/diagnosis were defined based on the World Bank Group proposed regions. New World cases grouped all cases infected in the American continent; Old World grouped all the remaining cases. Activity (travel, migration, refugee) was classified based on original articles’ information and considering travel as a broader category including military and missionary service, tourism, visiting friends and relatives, work stays and exchange student programs.
Only laboratory-confirmed leishmaniasis cases were included in this review. Methods and samples for diagnosis were included only when specified for each individual in the article. Besides counting the number of individuals in which each test was performed, the result of the test for each individual was registered: positive (suggestive or confirmatory of current Leishmania infection) or negative. Species/complex identification was only considered when the articles mentioned laboratory confirmation, even though the exact technique may not be specified. Even though some articles mentioned identification to the species level, for result analysis and discussion purposes, cases of species of the same complex are presented together, following the classification proposed by [1]:
-
Leishmania (Leishmania) subgenus: L. mexicana complex (L. mexicana, L. amazonensis, L. venezuelensis); L. donovani complex (L. donovani, L. infantum (=L. chagasi); L. tropica complex (L. tropica, L. killicki, L. aethiopica); L. major;
-
Leishmania (Mundinia) subgenus: L. martiniquensis; L. “siamensis”;
-
Leishmania (Viannia) subgenus: L. braziliensis complex (L. braziliensis, L. peruviana); L. guyanensis complex (L. guyanensis, L. panamensis); L. lainsoni; L. naiffi.
Clinical signs, symptoms, and laboratory findings were extracted, whenever available, using the terms contained in the original articles. Patients with splenomegaly, hepatomegaly or both were grouped under the same category. Patients with unspecific/constitutional symptoms were also grouped. For CL, lesion type was classified into four categories, following classical dermatological lesion classification nomenclature: ulcerated lesions; papular/nodular lesions; macular lesions, plaques and crusts; other (whenever this term was used in the original articles). Classification of mucosal (ML) and mucocutaneous (MCL) leishmaniasis cases was performed by the authors, following the definition proposed in the “Manual on case management and surveillance of the leishmaniases in the WHO European Region” [5], whenever clinical information provided allowed, and regardless of the article’s original classification. In articles with insufficient clinical information, ML/MCL classification was assumed according to the article [11,15]. Immunosuppression status included diabetes mellitus, malignancy, transplant, HIV infection and pharmacological immunosuppression (not-transplant related). Post-Kala-azar Dermal Leishmaniasis (PKDL), disseminated and diffuse CL were considered specifically when this term was used in the original article.

3. Results and Discussion

3.1. Human Leishmania Infection and Leishmaniasis

3.1.1. Visceral Leishmaniasis

Five hundred forty cases of non-endemic human VL were described within the selected period and criteria. In most cases for which the place of infection was described, it likely occurred in Europe (60.8%), followed by South Asia and East Asia (14.8%) and Sub-Saharan Africa (9.8%) (Table 1). Forty-one countries or territories were identified as likely places of infection for 302 patients (Figure 2; Supplementary Table S1).
Eighty-five percent of patients traveled to these regions, whereas 15% were migrants or refugees from these areas. Among travelers, most people were tourists, traveling for work or visiting friends and relatives; only three VL cases were described as military personnel: two deployed in Afghanistan [21] and one in Bangladesh [19]. Refugees were from Somalia (n = 17; [16]) and Ethiopia (n = 1; [17]), while migrants with VL were from Europe and Central Asia (n = 19; [25,36,44,60,208,214,216]), Sub-Saharan Africa (n = 4; [20,28,29]), Latin America (n = 2; [55,199]) and Middle East (n = 2; [10,20]). In one case, a transplacental transmission was described [45]. Patients were diagnosed in 22 countries, mostly in Europe (n = 434). Outside the European region, cases were diagnosed in Australia (n = 10, [28,36,45,57,64,211,251]), Kenya (n = 16, [16]), Kuwait (n = 36, [19]), Saudi Arabia (n = 35, [259]) and the USA (n = 8, [21,43,49,51,55,60,215]). The predominance of cases from the Mediterranean region likely reflects more intensive travel to southern Europe, especially in people from countries where most cases were diagnosed such as France (n = 107, [6,18,61,68]), the UK (n = 80, [22,38,50,52,58,201,204,207,210,214,219,252,253,261]) and Germany (n = 68, [8,20,25,27,33,35,37,40,44,46,47,53,56,63,198,203,250]). Additional factors for this finding could be stronger monitoring and reporting systems in countries where cases of endemic leishmaniasis also occur [283] and the presence of networks such as LeishMan [284].
Around 72% (164/227) of patients were male and the median age was 34.5 years old (range 4 months–86 years), with 29% (n = 42) of patients less than 10 years old and 18% of patients over 65 (n = 26) (Table 1; Supplementary Figure S1).
Clinical presentation of non-endemic cases showed many similarities with the classical description of VL from endemic areas [285,286,287]: fever, isolated or combined hepatomegaly/splenomegaly and constitutional symptoms were the signs/symptoms most commonly described (Table 2). Dermatologic manifestations were reported in nine cases, of which three were described as CL (with typical ulcerated lesions) [40,66,257], while six presented other symptoms such as hyperpigmentation, rash, erythroderma [19,31,35,55,204,252]. Rare and atypical manifestations, with the exception of two patients with isolated lymphadenopathy [37,198] and one with kidney involvement [29], were reported in immunocompromised patients, namely involvement of the eye (n = 1, [35]), lung (n = 2, [32,34]) gastrointestinal tract (n = 6 gastroduodenal, [28,197,261]; n = 4 colorectal, [48,204,252,261]; n = 1 with both, [35]).
Similarly, laboratory findings of 125 patients translated the natural history of the disease well known in endemic countries [286]: most patients had single or multiple lineage cytopenias, while elevation of liver enzymes and renal failure were less commonly described (Table 2). In 22 patients, laboratory findings were consistent with hemophagocytic lymphohistiocytosis (HLH) [17,26,44,49,50,52,59,68,206,214]. Although the association between leishmaniasis and HLH seems to be a rare finding in the pediatric population of endemic areas [288], cases occurring in infants have been reported in imported cases [44], so in children under 2 years of age traveling to endemic areas, leishmaniasis should be included in the differential diagnosis of secondary HLH.
The diagnostic approach was described for 343 patients (Table 3): microscopy and serology were the techniques most often used. Bone marrow aspiration or biopsy was the most commonly used biological samples for microscopy, polymerase chain reaction (PCR) and culture. Positivity in these samples was higher using PCR (96.6%), followed by microscopy (91.5%) and culture (88.6%). For PCR, blood was also commonly used (30.5%). Other samples where positive parasitological results were occasionally obtained included liver and lymph nodes, the last ones possibly representing part of the path for investigation of alternative diagnoses, such as lymphoma.
Table
Table 3. The diagnostic approach of human leishmaniasis.
Table 3. The diagnostic approach of human leishmaniasis.
DescriptionVL CL/MCL/ML
Frequency Patients TestedFrequency Tested PositiveReferencesFrequency Patients TestedFrequency Tested PositiveReferences
Microscopy84.8% (291/343)91.8% (302/329) 63.4% (1072/1690)84.3% (904/1072)
  Bone marrow84.5% (246/291)91.5% (225/246)[12,17,19,20,24,26,27,29,31,32,35,38,40,42,43,44,46,47,49,51,53,55,57,58,59,60,61,62,63,64,65,66,68,199,200,201,202,203,205,207,209,210,211,212,213,214,215,216,217,218,219,249,250,251,256,257,258,260,261,262]NRNANA
  Liver10.3% (30/291)90.0% (27/30)[17,21,26,32,36,202,216,257,261]NRNANA
  Spleen8.6% (25/291)92.0% (23/25)[16,17,23,38,206,216,252,257,261]NRNANA
  Lymph node1.7% (5/291)100% (5/5)[35,37,198,261]0.1% (1/1072)100% (1/1)[82]
  Blood1.0% (3/291)100% (3/3)[21,24,29]NRNANA
  Skin1.0% (3/291)100% (3/3)[66,257,261]96.7% (1037/1072)84.2% (873/1037) a[7,11,12,20,27,30,38,66,69,70,71,72,73,75,77,78,79,80,81,82,84,85,86,87,88,89,90,91,92,95,96,97,98,99,100,101,103,104,105,106,110,113,115,116,117,119,120,121,122,123,124,126,127,128,129,131,134,137,139,140,141,143,144,145,147,148,149,150,151,152,153,156,157,159,160,162,163,164,165,166,167,168,169,170,171,174,175,176,179,181,182,183,184,185,186,187,191,194,195,196,197,221,222,224,225,226,227,228,229,230,231,234,235,236,237,238,239,240,241,242,243,244,246,247,254,255,263,268,271,275,279,280,281]
  Other5.5% (16/291) b93.8% (15/16)[32]NRNANA
  Mucosa cNRNANA3.1% (33/1072)90.9% (30/33)[11,26,30,38,76,82,107,108,109,111,114,130,135,146,152,158,161,180,190,223,233,245]
Serology68.8% (236/343)95.2% (318/334) 6.8% (115/1690) d69.1% (85/123)
  DAT45.1% (97/215)96.9% (94/97)[16,38,42,52,257,259,261]6.1% (6/99)66.7% (4/6)[103,158]
  rK3944.2% (95/215)93.7% (89/95)[38,52,60,204,210,211,213,257,259,261,262,281]17.2% (17/99)64.7% (11/17)[114,119,158,174,190,277]
  IFAT41.4% (89/215)94.4% (84/89)[18,19,20,25,29,32,33,40,43,44,47,59,198,202,203,212,216,250,257]73.7% (73/99)71.2% (52/73)[11,71,80,89,101,104,107,119,129,135,138,143,179,226]
  ELISA13.0% (28/215)92.9% (26/28)[18,20,33,37,40,41,44,47,68,199,203,250]7.1% (7/99)57.1% (4/7)[70,89,135,144,170,176,179]
  WB1.9% (4/215)100% (4/4)[25,68,203,256]4.0% (4/99)100% (4/4)[104,121,135]
PCR51.6% (177/343)94.1% (206/219) 84.9% (1435/1690)97.2% (1398/1438)
  Bone marrow83.7% (118/141)96.6% (114/118)[12,20,21,22,24,26,27,29,32,33,40,42,44,45,47,48,49,50,51,52,57,58,59,61,62,63,64,65,66,68,199,209,210,211,212,214,215,250,253,260]NRNANA
  Blood30.5% (43/141)93.0% (40/43)[18,20,24,25,29,32,41,44,48,60,61,62,66,202,217,250,260]0.1% (2/1435)100% (2/2)[20]
  Liver7.1% (10/141)90.0% (9/10)[21,26,32,48,202]NRNANA
  Spleen4.3% (6/141)100% (6/6)[16,23,54,59,66,206]NRNANA
  Other2.8% (4/141) e100% (4/4)[28,29,48,204]NRNANA
  Lymph node1.4% (2/141)100% (2/2)[37,56]0.1% (2/1435)100% (2/2)[82,180]
  Mucosa cNRNANA4.0% (57/1435)96.5% (55/57)[11,30,38,76,77,82,107,109,111,114,129,130,133,135,142,146,158,161,173,179,180,190,223,233,245,273]
  SkinNRNANA96.0% (1378/1435)97.2% (1340/1378) f[7,9,11,12,20,26,28,30,38,45,61,65,66,70,75,76,77,78,79,82,83,87,89,91,92,93,94,95,96,97,98,100,102,104,105,106,107,109,110,111,114,116,117,119,121,122,123,124,126,127,128,129,130,132,133,134,135,136,137,138,139,140,141,142,143,144,145,146,147,149,150,151,153,156,157,158,159,161,162,164,165,166,167,168,170,171,172,173,174,175,176,177,178,179,180,181,182,185,186,187,188,189,190,191,192,193,194,195,196,197,223,225,226,227,229,230,231,233,235,236,238,239,240,241,242,243,244,245,246,247,255,266,268,271,273,275,278]
Culture17.5% (60/343)76.2% (48/63) 48.7% (823/1690)86.8% (714/823)
  Bone marrow76.1% (35/46)88.6% (31/35)[12,18,21,27,29,32,44,51,63,181,199,209,250]NRNANA
  Spleen19.6% (9/46)100% (9/9)[16,206]NRNANA
  Lymph node 4.3% (2/46)100% (2/2)[11,198]0.2% (2/823)100% (2/2)[82,180]
  Blood2.2% (1/46)100% (1/1)[29]NRNANA
  Liver2.2% (1/46)100% (1/1)[21]NRNANA
  Other2.2% (1/46) g100% (1/1)[32]NRNANA
  MucosaNRNANA1.8% (15/823)86.7% (13/15)[12,43,73,94,111,207,222,236,259]
  SkinNRNANA98.2% (808/823)86.5% (699/808) h[7,9,12,28,30,69,70,71,72,73,75,77,80,81,82,85,87,89,90,91,95,97,98,100,104,110,116,117,119,120,121,122,123,127,128,129,131,134,137,145,148,149,150,156,159,163,166,169,175,176,181,183,187,221,226,227,228,234,235,242,247,263,266,268,271,275,278]
Species/complex
  L. donovani complex98.8% (167/169)NA[9,10,11,16,20,21,22,24,25,26,27,28,29,32,33,37,40,44,45,47,48,49,51,52,54,57,59,60,61,62,63,64,66,68,198,199,202,206,209,210,211,212,214,256,260,261]See Figure 3NANA
   L. infantum + L. major0.6% (1/169)NANANRNANA
   L. subgenus Mundinia0.6% (1/169)NANANRNANA
a Skin biopsy in 474/581 (81.6%) patients; skin smear/scraping in 195/581 (33.6%); positivity in 419/474 (88.4%) and 145/195 (74.4%) of samples, respectively; unspecified technique (n = 491); b Gastric and/or duodenal (n = 9); colorectal (n = 5); 1 renal (n = 1); 1 bronchial biopsy (n = 1); c Excluding gastrointestinal and lower respiratory tract mucosa; d Including in 21 patients with MCL/ML; in these, positivity was reported in 82.1% of tests performed (23/28); e Colorectal (n = 2); gastric (n = 1); renal biopsy (n = 1); f Skin biopsy in 613/690 (88.8%) patients; skin smear/scraping in 115/690 (16.7%); positivity in 603/613 (98.4%) and 115/115 (100%) of samples, respectively; unspecified technique (n = 745); g Lung biopsy (n = 1); h Skin biopsy in 460/525 (87.6%) patients; skin smear/scraping in 67/525 (12.8%); positivity in 423/460 (92.0%) and 61/67 (91.0%) of samples, respectively; unspecified technique (n = 298); Abbreviations: VL, visceral leishmaniasis; CL, cutaneous leishmaniasis; MCL, mucocutaneous leishmaniasis; ML, mucosal leishmaniasis; PCR, polymerase chain reaction; ELISA, enzyme-linked immunosorbent assay; IFAT, immunofluorescence antibody test; DAT, direct agglutination test; rK39, rapid immunochromatographic test; NA, not applicable, NR, not reported.
Pathogens 11 00921 g003 550
Figure 3. Infecting species/complex in cases of cutaneous, mucocutaneous and mucosal leishmaniasis in: (a) Old World; (b) New World.
Figure 3. Infecting species/complex in cases of cutaneous, mucocutaneous and mucosal leishmaniasis in: (a) Old World; (b) New World.
Pathogens 11 00921 g003
Among serological techniques, indirect fluorescent antibody test (IFAT), direct agglutination test (DAT) and immunochromatographic test (ICT, rK39-based) were employed with similar frequency (40–45%), probably reflecting their more widespread availability in general, and especially in non-endemic countries/areas. The sensitivity and specificity of these tests in immunocompetent patients are considered to be high and therefore good choices for initial diagnosis [5]; in addition, quantitative serological tests (such as IFAT and DAT) are also useful for follow-up, as antibody titers tend to decay after successful treatment [5]; qualitative tests (such as ICT), on the other hand, offer a fast, point-of-care alternative for serological diagnosis.
All cases in which Leishmania species/complex was identified (n = 169) belonged to the L. donovani complex, except for one case caused by the subgenus Mundinia [253] (previously identified by the nomen nudum L. “siamensis” and later suggested to be L. martiniquensis [213]) and a co-infection caused by L. infantum/L. major [40]. Visceral disease caused by L. (Mundinia) species [289] and L. major has been rarely reported [290]. Leishmania major/L. donovani complex co-infections have been associated with visceral [291] and cutaneous disease [292], including disseminated CL in the context of HIV infection [293,294]. The case identified in this review was a patient chronically medicated with steroids and methotrexate.
Treatment strategies were reported in 256 cases (Table 4): formulations of amphotericin B (AmB) were used in 72% of these cases, pentavalent antimonials in 21%, which is in line with the WHO recommendations for treatment of VL in L. donovani complex endemic countries [5]; two cases were initially treated with combined therapy (liposomal amphotericin B-LAmB and miltefosine). Relapse or treatment failure occurred in 14% of the cases where treatment was known (n = 35) in 12% of patients initially treated with LAmB and 19% of patients initially treated with antimonials. Retreatments (n = 19, [21,32,35,44,47,51,55,58,66,252,260,261] often consisted of additional single or multiple courses of the same treatment strategy (53%, [44,47,51,55,58,66,260,261]) and rarely consisted in combined therapy [35]. Seventy-seven percent of the failures/relapses occurred in immunosuppressed patients [32,35,47,55,58,66,252,257,260,261]. Patients medically immunosuppressed by chemical or biological drugs or presenting immunodeficiencies (such as HIV infection/AIDS) are prone to VL relapses [295,296]; therefore, close monitoring until a sustained immune reconstitution has occurred is advisable [297].

3.1.2. Cutaneous, Mucocutaneous and Mucosal Leishmaniasis

According to selected criteria, 9771 cases of non-endemic human cutaneous/mucosal disease (Table 1) were described: 9642 CL, 90 MCL and 39 ML. Old World cases represented over 80% of the total. The two regions where most patients were presumably infected were the Middle East and Latin America and the Caribbean. Sixty-seven countries and territories were identified as likely places of infection for 8553 patients (Figure 4; Supplementary Table S2).
Two thousand three hundred thirty-eight (32.7%) patients traveled to these regions, whereas 67.7% were migrants or refugees from these areas. Among travelers, 1027 (43.9%) were described as military personnel: 521 (50.7%) deployed in Iraq [46,292], 183 (17.8%) in Afghanistan [45,112,279] and 167 (16.2%) and 21 (2.0%) in military training in Belize [69,87,96,105,147,163,267,269] and French Guiana [69,136,151], respectively. Most of CL in refugees was reported in individuals from Syria (n = 4600, 99.6% of cases, [157,172,181,188,195,246,274]). Migrant individuals (n = 186) were infected most often in Latin America (40.6%, [30,101,107,132,139,149,154,193,197,224,276]) and South Asia (27.3%, [20,28,45,68,95,168,187,220]). Overall, migrants represented a small percentage (<15%) of CL, MCL and ML cases from the respective countries, except for: Paraguay (82%, [276]), Colombia (71%, [101]), Nicaragua (33%, [149]), Algeria (32%, [95]), Panama (27%, [139]) and Burkina Faso (26%, [30,95]). Around 58% (3820/6569) of patients were male and the median age was 31 years old (ranging from 9 months to 86 years). The age distribution is represented in Supplementary Figure S2. Reports of the demography of military personnel and refugees likely explain why people aged 20–30 years old were the most affected by cutaneous and mucosal disease [298].
Patients were diagnosed in 35 countries; most of the cases were in the Middle East, Europe, and North America (Table 1). In these three regions, countries with the largest share of diagnosis were Lebanon (57.0%, [192,282]), France (13.4%, [6,61,81,108,121,134,136,193], the USA (6.1%, [72,80,84,88,92,93,110,114,117,120,122,123,127,139,141,142,149,150,159,163,169,175,179,180,197,221,224,229,234,235,238,239,243,244,247,263,266,279]), the Netherlands (5.0%, [12,65,90,106,112,137,162,190,229,240,269]) and the United Kingdom (4.8%, [7,38,82,87,91,94,105,109,130,140,143,147,155,159,165,171,220,222,223,225,267]). Countries outside these three regions where cases were diagnosed were: Australia (n = 85, [28,45,85,98,115,196,230]), Venezuela (n = 29, [101]), China (n = 12, [156,268,271]), Brazil (n = 10, [276,281]), Bangladesh (n = 6, [103,145,160,174]), Cuba (n = 6, [166,237]), Japan (n = 4, [190,219,242]), Singapore (n = 2, [69]), India (n = 1, [183]), Mexico (n = 1, [176]), South Korea (n = 1, [184]) and Taiwan (n = 1, [186]).
The diagnostic approach was described for 1690 patients (Table 3). Although skin biopsy allows for differential diagnosis in suspected cases of CL, the sensitivity of well-performed skin scrapings is similar [299], and the procedure is less invasive, which could explain why these biological samples were used in most cases. The positivity rates reported with PCR (97.2%) were considerably higher than with microscopy (84.2%) or culture (86.5%). Other biological samples occasionally used for diagnosis included mucosal biopsies (n = 61, in ML/MCL cases), blood (n = 2) and lymph node (n = 2, in MCL/ML cases).
Even though the use of serological methods for the detection of antibodies against Leishmania in CL should be discouraged because of their low sensitivity and variable specificity [5], the performance of serological testing was reported in 115 patients, yielding positive results in 69.1% of the samples tested. IFAT was the technique most commonly used (73.7% of serological tests), followed by ICT (17.2%). Reporting of serological testing was proportionally more common in MCL/ML cases (21/61 versus 94/1629 in CL) and positivity rates were also higher (82.1%); this finding is in line with the WHO recommendation in the European region to include serological methods in the laboratory diagnosis of MCL/ML [300]. Infecting Leishmania species/complex was described in 3495 individuals and followed the relative distribution shown in Figure 3, for Old World and New World disease. The distribution of species/complex for each country of infection is represented in Figure 5 and Supplementary Table S3.
Overall, the results demonstrated that human movements have led to an increase in the number of imported CL cases due to non-indigenous Leishmania species in both endemic and non-endemic countries. Although the potential risk of introducing these exotic Leishmania species into non-endemic areas is low, since for most of them their main reservoirs hosts are absent, the vectorial competence of local sand fly species must be considered, as it may allow for successful adaptation of non-indigenous Leishmania species with important epidemiological consequences [301]. The most expressive group of imported cutaneous cases was represented by refugees from war zones in the Middle East diagnosed mostly in neighboring countries (such as Lebanon and Turkey) and reflecting how the ongoing Syrian war has dramatically increased the incidence of CL in these countries [302]. The refugee status of these people in the host countries could be an important factor deterring an early diagnosis of disease. Some countries and centers, such as the ECDC [303], have produced and implemented guidelines and recommendations for the initial healthcare screening of migrants and refugees. Although leishmaniasis is only briefly addressed in these documents, promoting a complete assessment that includes skin checks [304] will probably help shorten onset to treatment intervals in CL. This shortening could be particularly relevant in the European context since untreated CL lesions harbor vector infective parasites [305], which could infect competent/permissive vectors and allow the establishment of anthroponotic cycles for non-endemic Leishmania species. Phlebotomus sergenti, a specific vector of L. tropica, the species most imported with refugees, is widely distributed in Southern Europe [306] and new endemic foci could emerge through the introduction of infected humans in areas where the sand fly species are present [307]. Other phlebotomine species present in the Mediterranean region, namely P. perniciosus and P. tobbi, have also been shown to be susceptible to L. tropica infection under experimental conditions [308,309] and capable of transmitting viable parasites to vertebrate hosts (for P. perniciosus), representing an additional threat of its introduction in countries where these permissive sand fly species are present [310]. The movement of refugees across borders has also been linked to the detection of new L. tropica zymodemes in endemic areas. In Crete, where L. tropica infection is diagnosed sporadically [310], a new zymodeme was detected from an Afghan refugee and later on a local (non-traveler) dog [138]. DNA of non-endemic Leishmania species has been detected in phlebotomine sand flies in refugee camps in Greece [311].
Although the risk of introduction of L. major seems to be low, as its gerbillids reservoirs are not present in Europe [310,312], voles of the genus Microtus have recently been implicated as L. major reservoir hosts in a CL focus in northern Israel [313]. As such, the possibility that L. major, having adapted to voles, spreads north into Turkey and southern Europe, where reservoir hosts and vectors exist sympatrically should not be neglected. Furthermore, the presence of European sand fly species permissive to this parasite species, such as P. perniciosus [314] and P. tobbii [315], should also be kept in mind. Indeed, the presence of L. major in Europe has already been reported, namely in Portugal, through the detection of its DNA in sand flies [316] and a cat [317], and of L. infantum/L. major hybrids in HIV-infected patients [291] and a cat [317].
Phlebotomine vectors for L. infantum are also permissive for L. donovani and are widely distributed across Southern Europe, raising concern for the introduction of this parasite species, as has already been documented in Cyprus in humans and dogs [318]. Hybridization between L. infantum and L. donovani is also concerning and has been demonstrated in Turkey [319].

3.1.3. Clinical Aspects and Management of Cutaneous Leishmaniasis

Regarding clinical presentation (Table 5), OW disease presented as single lesions in 58.8% of cases, preferentially located in the head and neck (50.6%) (especially in the cheeks—13/36, [119,126,137,138,148,153,168,175,232,242,246]—and nose—12/36, [45,113,126,132,134,145,152,153,196,230,246]) with the region of the trunk being the least affected (2.0%). Patients presented ulcerated lesions in 56.1% of cases, but other lesion types were also frequently seen, namely papules (24.9%) and plaques (20.2%). Besides cutaneous lesions, some patients presented lymphadenopathy (n = 21; 1.2%). Management strategy was described in 506 patients (Table 6): 282 (55.7%) received systemic treatment, 172 (34.0%) local treatment, 4 (0.8%) combined local and systemic treatment and 48 (9.5%) no treatment. A total of 65 failures or relapses were reported, representing 12.8% of cases [30,69,83,85,86,95,112,115,123,132,134,135,145,152,153,164,176,180,227,235,238,244]. When retreatment was described (n = 28, [30,83,85,86,112,115,123,134,135,145,152,164,176,180,227,235,238,244]), it most often consisted of a different strategy and/or drug (93.1%, [83,85,86,112,115,123,132,134,135,145,152,153,164,176,180,227,237,238,244]), especially systemic therapy (58.6%, [83,112,115,123,132,134,135,145,164,180,227,235,244]) (with LAmB being the drug of choice for 64.7% of these cases, [113,122,135,164,180,235]). Combination of drugs represented 34.5% of retreatments [30,112,115,135,238].
The clinical presentation for each of the three most common OW species/complex is summarized as follows:
-
L. donovani complex: predominantly single lesions; involving mostly the head/neck and upper limbs, often non-ulcerative (especially plaques/crusts);
-
L. major: predominantly multiple lesions; involving mostly the limbs, mostly ulcerative;
-
L. tropica: single or multiple lesions; predominantly in the head/neck and upper limbs, often non-ulcerative.
Other species/complexes were less often reported, and their epidemiological and clinical features were:
-
L. aethiopica: 13 cases reported [7,10,11,119,132,133,136,247,275,277], six of them imported from Ethiopia [10,11,136,247]; only three cases described lesions [119,132,247]: two of them as single lesions in the face or trunk [121,247] and one as multiple lesions in the face [132]; in two patients the lesions were papular/nodular [119,247] and in one it was a plaque/crust [132]; management strategy was described in six cases (one no treatment, [247], two topical with intralesional antimonial and cryotherapy, [277], and three systemic with miltefosine or LAmB, [119,132,133]). Relapses were not reported in any of the cases.
Most of the CL caused by NW Leishmania species were presented as single lesions (79.0%; n = 290) and was preferentially located in the upper (41.2%) and lower (34.5%) limbs (Table 5). The head and neck regions were affected in 28.1% of cases (especially the ears—11/31, [69,93,122,128,129,159,162,177,189,194,228]). Patients frequently presented ulcerated lesions (77.2% of cases). One hundred and twenty-eight patients (30.5%) presented lymphadenopathy. Management strategy was described in 603 patients: 521 (86.4%) received systemic treatment, 42 (7.0%) local treatment, 6 (1.0%) combined local and systemic treatment and 34 (5.6%) no treatment (Table 7). A total of 85 failures or relapses were reported, representing 14.1% of cases [20,30,69,77,82,92,96,97,100,116,120,121,125,126,128,129,139,140,146,150,165,173,177,178,179,180,194,228,269]. When retreatment was described (n = 44, [30,82,92,96,97,100,116,120,121,125,126,128,129,139,140,146,150,173,177,178,179,180,194,228,269]), it most often consisted of a different strategy and/or drug (92.3%, [30,82,92,96,97,100,116,120,121,125,126,128,129,139,140,146,150,173,177,178,179,180,194,228,269]), especially systemic therapy (89.7%, [30,77,82,92,96,97,100,116,120,121,126,128,129,139,146,168,177,179,180,194,228,269]) (with LAmB used in 51.4% of systemic retreatments, [97,100,113,126,129,180,194,228,269]). Combination of drugs represented 17.9% of retreatments [30,92,116,121,129,152,179,194].
For New World disease, relevant findings by species/complex can be summarized as follows, for the three most common species/complexes:
-
L. braziliensis complex: predominantly single lesions; most often in the lower and upper limbs; commonly ulcerative; more frequently associated with lymphadenopathy;
-
L. guyanensis complex: predominantly multiple lesions; involving mostly the upper limbs; ulcerative; often associated with lymphadenopathy;
-
L. mexicana complex: predominantly single lesions; mostly in the head/neck; mostly ulcerative, but also frequently plaques/crusts.
Other species/complexes were less often reported, and their epidemiological and clinical features were:
-
L. naiffi: nine cases were reported [12,69,106,133,136], two from French Guiana [69,136], 2 from Surinam [106] one from Brazil [133] and four from unspecified countries of Latin America; only three cases described lesions (2/3 single, 1/3 multiple; 1/3 upper limbs, 1/3 lower limbs, 1/3 face; 1/3 ulcer, 2/3 plaque/crust, [16,108]); of the three cases where management strategy was described [108], only one was treated, with topical paromomycin [133], and no failures/relapses were reported;
-
L. lainsoni: only one case reported [69], imported from Brazil; multiple ulcerated lesions in the upper limb; no treatment description available;
-
L. martiniquensis: only one case reported [69], imported from the French Caribbean; multiple papular lesions, in the upper limbs; classified as PKDL in the original article; no treatment description available.
Atypical cutaneous presentations were reported in 14 cases in both OW/NW: nine disseminated leishmaniasis [10,69,133,185,192,235,260], four PKDL [11,28,69] and one diffuse leishmaniasis [8]. Skin coinfection or superinfection was described in eight patients: seven bacterial [94,121,185,196,197] and one fungal [185]. Staphylococcus aureus [185,197] and Streptococcus pyogenes [185] were the most common pathogens identified (2 cases each).

3.1.4. Particular Aspects of Mucocutaneous and Mucosal Leishmaniasis

Ninety cases of MCL and 39 cases of ML were reported (Table 8). Infection in these cases occurred in 22 different countries, with approximately half of MCL/ML cases (when country of infection was known) reported from Bolivia (n = 25|5, [30,77,82,107,108,173,180,228] and Spain (n = 6|12, [11,69,109,130,132,135,153,155,158,245]. Other countries (1 to 7 cases) were: Greece [11,69], Italy [69], France [20,69], Croatia [111], Peru [11,20,80,177], Ecuador [8,11], Brazil [9,102], Colombia [82], Venezuela [95,281], Suriname [12,64], French Guiana [66,69], Argentina [179], Belize [82,223], Nicaragua [69], Panama [154], Costa Rica [14,69,74], Cameroon [11], India [6], Turkey [69], Saudi Arabia [114].
Percentage of cases presenting as MCL/ML varied by species: 8.8% of individuals infected with L. braziliensis complex presented MCL/ML; for L. donovani complex, a disease with mucosal involvement was present in 6.0% of total cases (including VL), but 9.6% of skin/mucosal infection. In the OW, MCL/ML represented 0.6% of cutaneous/mucosal cases, although it represented 14.3% when considering Europe alone; in the NW, MCL/ML represented 3.8%. In countries with over 20 cases of leishmaniasis reported, presentation of the disease with mucosal involvement or progression to this form of disease was more common in the following countries: Suriname (where it represented 15.9% of total cases), Bolivia (12.7%), Spain (9.7%), France (12.5%) and Greece (13.9%).
For MCL, the median age was 37 years old and 74.6% of patients were male. Infection likely occurred in the New World for 80.6% of individuals, mostly in South America. Old World cases mostly originated from Europe/Central Asia (85.7% of OW MCL cases).
Of 38 patients where the description of the location of mucosal lesions was available, exclusively nasal involvement was more common (26/38). In 43 cases, clinical aspects of cutaneous lesions were described. As the time of onset of mucosal lesions after cutaneous lesions varied from simultaneous to 50 years [102], travelers, especially those traveling to the NW, who develop cutaneous lesions should be warned to remain vigilant for symptoms of mucosal involvement, including many years after travel. Cutaneous lesions in MCL cases were often multiple (52.6% of patients; average 3.58 lesions), ulcerative (69.6%) and located in the head or neck (60.0%). Nasal obstruction was the most reported symptom (57.9%), followed by nasal discharge (34.2%, with epistaxis in 30.8% of these cases). Other symptoms included lacrimal gland obstruction [171] and deafness [161] in one case each. Though lymphadenopathy and/or lymphangitis were reported in 11.1% of patients, lymph node samples were rarely used for the diagnosis (3.6%). Species/complex identification was performed and reported in 49 cases (Table 8). All cases of MCL where management strategy was known were treated (n = 51); systemic treatment was used in 96.0% of cases, most often LAmB (43.1%, [20,77,173,192]) and intramuscular antimonials (33.1%, [38,79,81,107,108,142,173,223]). A combination of drugs was used initially in five cases (9.8%, [30,102,179]). Fourteen failures or relapses were reported (27.5%, [20,30,82,129,146,153,173,177,179,180,228]); all of them were retreated with a different secondary regimen, including combination therapy [30,179].
For ML, the median age was 64 years old and 78.8% of patients were male. Infection likely occurred in the Old World for 76.9% of individuals (85.7% of these from Europe/Central Asia). Eleven different countries were identified as likely places of infection for 29 patients.
Of 27 patients where the description of the location of mucosal lesions was available, 10 (37.0%) had exclusively nasal involvement, eight had exclusively oral involvement (including four cases of tongue leishmaniasis), eight had laryngeal involvement and one intestinal involvement (no evidence of visceral disease) [26]. Hoarseness, nasal obstruction, and nasal discharge were frequently reported signs/symptoms (16–42%). In three cases, mucosal coinfection with Candida species was reported (oral/pharyngeal candidiasis, [158,177,204]).
Species/complex identification was performed and reported in 30 cases (Table 8). Systemic therapy was used in all cases of ML where therapeutic approach was described (n = 24), most often LAmB (33.3%, [111,114,130,135,154,161,190]), miltefosine (33.3%, [132,152,158,173,180]) and intramuscular antimonials (25.0%, [76,82,109,133,233]). A combination of drugs was used initially in two cases (8.3%, [30]). Three failures or relapses were reported (12.5%, [30,133,135]); two of these cases were subsequently treated with a combination of LAmB and miltefosine [30,135].
The analysis of all the CL cases allowed for a comparison of clinical presentation and outcome, which differed not only between OW and NW cases but also between species, as outlined in previous works [15,320]. It is also important to note that travel between endemic regions for different Leishmania species/strains can potentiate coinfection and lead to the generation of new hybrids, with different pathogenicity [291], the different clinical presentations with the consequent increase in the difficulty of diagnosing and management [321,322]. By combining this information with the relative abundance of different species in imported cases from each country, an approach for the diagnosis and management of CL, MCL and ML cases in non-endemic settings is suggested (Figure 6). This algorithm represents the authors’ opinions based on the results of this review and aims to help clinicians to judge the likely infecting species and adapt treatment strategies accordingly, in situations where laboratory confirmation of the infecting species/complex cannot be performed in clinically relevant time. Additionally, it should be noted that recommended treatments are not always available in non-endemic settings and, when available, medical teams may not be very familiar with their use.

3.1.5. Particular Aspects in Immunosuppressed Patients

Data on the immunological status of patients was gathered whenever available, to emphasize the contribution of new immunosuppression factors to the progression of the disease and understand the changing epidemiology of leishmaniasis in non-endemic countries, similarly to endemic areas [323]. In immunosuppressed individuals, even when asymptomatic, Leishmania infection can be transmitted to phlebotomine vectors [324], and, in this way, these patients could play a role in the maintenance of the cycle of the parasite.
A total of 214 leishmaniasis cases in patients with one or more recognized factors of immunosuppression were reported (Table 9). These patients represented 41.0% of ML cases, 21.7% of VL cases, 12.2% of MCL cases and 0.7% of CL cases.
Even though almost half of the immunosuppressed patients with VL were people living with HIV/AIDS, approximately one-fourth were patients chronically medicated with immunosuppressive drugs for inflammatory and auto-immune disorders. Of these, methotrexate, steroid and anti-TNFα were the most commonly implicated. In ML cases, immunosuppressive therapy was the most common form of immunosuppression (over half of cases), reinforcing that these patients represent one of the groups at risk of developing this clinical condition [5]. A high proportion of these cases (~25% of VL and ~50% of ML) were attributed to chronic medication with anti-TNFα. The association of anti-TNFα therapy with symptomatic Leishmania infection has been described in many case reports [325] and reviewed in previous articles [326]. Though the use of anti-TNFα has been increasing, no clinical trials have properly addressed the risk of progression to disease in previously and newly infected patients compared to non-medicated patients, and no strategies for the treatment of asymptomatic individuals have been prospectively researched, although clinical (and laboratory) monitoring could be suggested [323]. As such, no evidence currently supports the screening of individuals before starting treatment and there is no consensus on when and how to treat Leishmania infection in asymptomatic cases. Additionally, guidance on secondary prophylaxis in non-HIV immunosuppressed patients is lacking. Future research should address this gap of knowledge regarding appropriate prevention and management in emerging groups of immunosuppressed patients.
In addition, and as most of CL/MCL/ML in immunosuppressed patients was associated with infection in the Old World with the L. donovani complex, ear nose and throat clinicians should be aware of leishmaniasis as a differential diagnosis of oral and laryngeal lesions in immunocompromised people who traveled to Leishmania endemic areas, namely to the Mediterranean region.
Most immunosuppressed patients received systemic treatment and relapse, or failure rates were higher than in the general population for both VL (21.6% vs. 13.7%) and CL/MCL/ML (22.2% vs. 12.8–14.1%) (Table 9).

4. Conclusions

More than 10,000 cases of non-endemic leishmaniasis were reported in humans between 2000 and 2021, reflecting the impact of this disease on global tourism and migration and the movement of people (Box 1).
Drivers of changing patterns in epidemiology included the same as in endemic settings, namely conflict and war, as well as host factors such as immunosuppression (both natural and iatrogenic). Increased clinical management and surveillance of non-endemic cases (by physicians, especially dermatologists) could improve individual health and mitigate the public health risk of introducing Leishmania into new areas where favorable environmental conditions and permissive vectors exist. Strengthening surveillance and systematically combining animal and human data into an integrated platform, following a One Health approach (as proposed in a recent ECDC report [327]), could be the key to addressing the risk of leishmaniasis introduction associated with increased human and animal mobility.
Box 1. Main findings.
  • Over 10,000 non-endemic cases of human leishmaniasis were reported in the literature from 2000–2021, most commonly CL, followed by VL and ML/MCL.
  • VL resulted from travel to Europe in most cases; approximately half of the patients were children or elderly; fever, hepatosplenomegaly and pancytopenia were the most common findings; atypical presentations such as isolated lymphadenopathy, gastrointestinal and pulmonary involvement were described; the diagnosis was commonly made by microscopic examination of bone marrow biopsy/aspiration and/or serology; L. donovani complex was implied in almost all cases; LAmB was the drug most often used for treatment.
  • Most CL cases were diagnosed in refugees from the Middle East, migrants from Latin America and South Asia and military personnel deployed in Asia; diagnosis relied on skin scraping and/or biopsy, with positivity rates higher for PCR than microscopy or culture; L. tropica and L. major were the two most common species in the Old World, while L. braziliensis complex and L. guyanensis complex were predominant in the New World; the number, type and location of lesions differed between species/complexes, as well as the therapeutic strategies used and the relapse rates reported; L. aethiopica, L. naiffi, L. lainsoni and L. martiniquensis infections were rarely described.
  • MCL was reported in younger individuals, infected in the New World, most often by L. braziliensis complex; nasal mucosa was more often involved, and lymphadenopathy was common; the time between cutaneous and mucosal lesions varied from simultaneous to fifty years.
  • ML was diagnosed mostly in older patients, infected in the Old World, most often by L. donovani complex; oral and laryngeal mucosa involvement was frequently described.
  • Immunosuppressed patients represented a significant share of ML and VL cases; the two most common causes for immunosuppression were HIV/AIDS infection and chronic therapy, where anti-TNFα drugs represented the largest group; relapse/failure rates were higher in these patients.
  • Non-endemic leishmaniasis represents an individual health problem, especially for refugees and immunosuppressed people; but also, a public health concern, related to the risk of introduction of the disease in new areas.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/pathogens11080921/s1, Figure S1: Age distribution of visceral leishmaniasis cases; Figure S2: Age distribution of cutaneous, mucocutaneous and mucosal leishmaniasis cases; Table S1: References of cases of visceral leishmaniasis diagnosed, by country of travel or migration; Table S2: References of cases of cutaneous, mucocutaneous, and mucosal leishmaniasis diagnosed, by country of travel or migration; Table S3: References of identifications of species/complex by country in the Old and New Worlds.

Author Contributions

R.R.: Methodology, Validation, Formal analysis, Investigation, Writing—Original Draft. A.P.: Validation, Formal analysis, Writing—Original Draft. C.M.: Conceptualisation, Methodology, Validation, Writing—Review & Editing, Supervision. All authors have read and agreed to the published version of the manuscript.

Funding

The authors would like to acknowledge Fundação para a Ciência e a Tecnologia, I.P. (FCT) for funding through contract GHTM-UID/Multi/04413/2020. R.R. was supported by the Portuguese Ministry of Education and Science (via FCT) through a Ph.D. grant (UI/BD/151067/2021).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Conflicts of Interest

The authors declare that they have no competing interest.

References

  1. Akhoundi, M.; Downing, T.; Votýpka, J.; Kuhls, K.; Lukeš, J.; Cannet, A.; Ravel, C.; Marty, P.; Delaunay, P.; Kasbari, M.; et al. Leishmania Infections: Molecular Targets and Diagnosis. Mol. Aspects Med. 2017, 57, 1–29. [Google Scholar] [CrossRef] [PubMed]
  2. Solano-Gallego, L.; Mirá, G.; Koutinas, A.; Cardoso, L.; Pennisi, M.G.; Ferrer, L.; Bourdeau, P.; Oliva, G.; Baneth, G. LeishVet Guidelines for the Practical Management of Canine Leishmaniosis. Parasit Vectors 2011, 4, 86. [Google Scholar] [CrossRef] [PubMed]
  3. WHO Global Health Observatory: Leishmaniasis. Available online: https://www.who.int/data/gho/data/themes/topics/gho-ntd-leishmaniasis (accessed on 2 March 2022).
  4. Leishmaniasis. Available online: https://www.who.int/news-room/fact-sheets/detail/leishmaniasis (accessed on 2 March 2022).
  5. Word Health Organization (WHO). Manual on Case Management and Surveillance of the Leishmaniases in the Who European Region; Word Health Organization (WHO): Geneva, Switzerland, 2017. [Google Scholar]
  6. Lachaud, L.; Dedet, J.P.; Marty, P.; Faraut, F.; Buffet, P.; Gangneux, J.P.; Ravel, C.; Bastien, P.; Working Group for the Notification of Human Leishmanioses in France. Surveillance of Leishmaniases in France, 1999 to 2012. Euro. surveill. 2013, 18, 20534. [Google Scholar] [CrossRef] [PubMed]
  7. Wall, E.C.; Watson, J.; Armstrong, M.; Chiodini, P.L.; Lockwood, D.N. Epidemiology of Imported Cutaneous Leishmaniasis at the Hospital for Tropical Diseases, London, United Kingdom: Use of Polymerase Chain Reaction to Identify the Species. Am. J. Trop. Med. Hyg. 2012, 86, 115–118. [Google Scholar] [CrossRef]
  8. Weitzel, T.; Mühlberger, N.; Jelinek, T.; Schunk, M.; Ehrhardt, S.; Bogdan, C.; Arasteh, K.; Schneider, T.; Kern, W.V.; Fätkenheuer, G.; et al. Imported Leishmaniasis in Germany 2001–2004: Data of the SIMPID Surveillance Network. Eur. J. Clin. Microbiol. Infect. Dis. 2005, 24, 471–476. [Google Scholar] [CrossRef]
  9. Fernández-Arévalo, A.; Ballart, C.; Muñoz-Basagoiti, J.; Basarte, L.; Lobato, G.; Arnau, A.; Abras, A.; Tebar, S.; Llovet, T.; Lami, P.; et al. Autochthonous and Imported Tegumentary Leishmaniasis in Catalonia (Spain): Aetiological Evolution in the Last Four Decades and Usefulness of Different Typing Approaches Based on Biochemical, Molecular and Proteomic Markers. Transbound. Emerg. Dis. 2021, 69, 1404–1418. [Google Scholar] [CrossRef]
  10. di Muccio, T.; Scalone, A.; Bruno, A.; Marangi, M.; Grande, R.; Armignacco, O.; Gradoni, L.; Gramiccia, M. Epidemiology of Imported Leishmaniasis in Italy: Implications for a European Endemic Country. PLoS ONE 2015, 10, e0129418. [Google Scholar] [CrossRef]
  11. Söbirk, S.K.; Inghammar, M.; Collin, M.; Davidsson, L. Imported Leishmaniasis in Sweden 1993-2016. Epidemiol. Infect. 2018, 146, 1267–1274. [Google Scholar] [CrossRef]
  12. Bart, A.; van Thiel, P.P.; de Vries, H.J.; Hodiamont, C.J.; van Gool, T. Imported Leishmaniasis in the Netherlands from 2005 to 2012: Epidemiology, Diagnostic Techniques and Sequence-Based Species Typing from 195 Patients. Euro. Surveill. 2013, 18, 20544. [Google Scholar] [CrossRef]
  13. Boggild, A.K.; Caumes, E.; Grobusch, M.P.; Schwartz, E.; Hynes, N.A.; Libman, M.; Connor, B.A.; Chakrabarti, S.; Parola, P.; Keystone, J.S.; et al. Cutaneous and Mucocutaneous Leishmaniasis in Travellers and Migrants: A 20-Year GeoSentinel Surveillance Network Analysis. J. Travel Med. 2019, 26, taz055. [Google Scholar] [CrossRef]
  14. Flores-Figueroa, J.; Okhuysen, P.C.; von Sonnenburg, F.; Dupont, H.L.; Libman, M.D.; Keystone, J.S.; Hale, D.C.; Burchard, G.; Han, P.V.; Wilder-Smith, A.; et al. Patterns of Illness in Travelers Visiting Mexico and Central America: The GeoSentinel Experience. Clin. Infect. Dis 2011, 53, 523–531. [Google Scholar] [CrossRef]
  15. Guery, R.; Walker, S.L.; Harms, G.; Neumayr, A.; van Thiel, P.; Gangneux, J.P.; Clerinx, J.; Söbirk, S.K.; Visser, L.; Lachaud, L.; et al. Clinical Diversity and Treatment Results in Tegumentary Leishmaniasis: A European Clinical Report in 459 Patients. PLoS Negl. Trop. Dis. 2021, 15, e0009863. [Google Scholar] [CrossRef]
  16. Boussery, G.; Boelaert, M.; van Peteghem, J.; Ejikon, P.; Henckaerts, K. Visceral Leishmaniasis (Kala-Azar) Outbreak in Somali Refugees and Kenyan Shepherds, Kenya. Emerg. Infect. Dis. 2001, 7, 603–604. [Google Scholar] [CrossRef]
  17. Chalupa, P.; Vanista, J.; Nohynkova, M. The Review of Imported Visceral Leishmaniosis in the Czech Republic. Bratisl. Lek. Listy. 2001, 102, 84–91. [Google Scholar]
  18. Mégarbane, B.; Bruneel, F.; Cazals-Hatem, D.; Adle-Biassette, H.; Houze, S.; Wolff, M.; Régnier, B. A Strange Disease of the Plateaux. Visceral Leishmaniasis. Rev. Med. Interne. 2001, 22 (Suppl. S2), 219–222. [Google Scholar] [CrossRef]
  19. Iqbal, J.; Hira, P.R.; Saroj, G.; Philip, R.; Al-Ali, F.; Madda, P.J.; Sher, A. Imported Visceral Leishmaniasis: Diagnostic Dilemmas and Comparative Analysis of Three Assays. J. Clin. Microbiol. 2002, 40, 475–479. [Google Scholar] [CrossRef]
  20. Harms, G.; Schönian, G.; Feldmeier, H. Leishmaniasis in Germany. Emerg. Infect. Dis. 2003, 9, 872–875. [Google Scholar] [CrossRef]
  21. Centers for Disease Control and Prevention (CDC). Two Cases of Visceral Leishmaniasis in U.S. Military Personnel—Afghanistan, 2002–2004. MMWR Morb. Mortal. Wkly. Rep. 2004, 53, 265–268. [Google Scholar]
  22. Williams, M.J.; Korsheed, S.; Goddard, A.F.; Venkatesan, P. Hepatosplenomegaly in a Patient Returning from Spain. Br. J. Hosp. Med. 2006, 67, 670. [Google Scholar] [CrossRef]
  23. Visser, L.; Verweij, J. Clinical Reasoning and Decision-Making in Practice. A Young Boy with Fever, Pancytopenia and an Enlarged Spleen. Ned. Tijdschr. Geneeskd. 2006, 150, 2169–2170. [Google Scholar]
  24. Agteresch, H.J.; van’t Veer, M.B.; Cornelissen, J.J.; Sluiters, J.F. Visceral Leishmaniasis after Allogeneic Hematopoietic Stem Cell Transplantation. Bone Marrow Transpl. 2007, 40, 391–393. [Google Scholar] [CrossRef] [PubMed]
  25. Hoffmann-Tonn, K.; Geis, S.; Peckelsen, C.; Berna, G.; Fleischmann, E.; Bretzel, G.; Löscher, T. Acute Febrile Disease with Splenomegaly and Pancytopenia. A 66-Year-Old Greek Patient with a Prosthetic Mitral Valve. Internist 2007, 48, 731–736. [Google Scholar] [CrossRef] [PubMed]
  26. Weisser, M.; Khanlari, B.; Terracciano, L.; Arber, C.; Gratwohl, A.; Bassetti, S.; Hatz, C.; Battegay, M.; Flückiger, U. Visceral Leishmaniasis: A Threat to Immunocompromised Patients in Non-Endemic Areas? Clin. Microbiol. Infect. 2007, 13, 751–753. [Google Scholar] [CrossRef] [PubMed]
  27. Hagenah, G.C.; Wündisch, T.; Eckstein, E.; Zimmermann, S.; Holst, F.; Grimm, W.; Neubauer, A.; Lohoff, M. Sepsis-like Disease in an Immunocompromised Patient with a Travel History to Mallorca. Internist 2007, 48, 727–730. [Google Scholar] [CrossRef]
  28. Stark, D.; van Hal, S.; Lee, R.; Marriott, D.; Harkness, J. Leishmaniasis, an Emerging Imported Infection: Report of 20 Cases from Australia. J. Travel Med. 2008, 15, 351–354. [Google Scholar] [CrossRef]
  29. Beltrame, A.; Arzese, A.; Camporese, A.; Rorato, G.; Crapis, M.; Tarabini-Castellani, G.; Boscutti, G.; Pizzolitto, S.; Calianno, G.; Matteelli, A.; et al. Acute Renal Failure Due to Visceral Leishmaniasis by Leishmania infantum Successfully Treated with a Single High Dose of Liposomal Amphotericin B. J. Travel Med. 2008, 15, 358–360. [Google Scholar] [CrossRef]
  30. Pérez-Ayala, A.; Norman, F.; Pérez-Molina, J.A.; Herrero, J.M.; Monge, B.; López-Vélez, R. Imported Leishmaniasis: A Heterogeneous Group of Diseases. J. Travel Med. 2009, 16, 395–401. [Google Scholar] [CrossRef]
  31. Neghina, R.; Neghina, A.M.; Merkler, C.; Marincu, I.; Moldovan, R.; Iacobiciu, I. Importation of Visceral Leishmaniasis in Returning Romanian Workers from Spain. Travel Med. Infect. Dis. 2009, 7, 35–39. [Google Scholar] [CrossRef]
  32. Buonomano, R.; Brinkmann, F.; Leupin, N.; Boscacci, R.; Zimmermann, A.; Müller, N.; Fux, C.A. Holiday Souvenirs from the Mediterranean: Three Instructive Cases of Visceral Leishmaniasis. Scand. J. Infect. Dis. 2009, 41, 777–781. [Google Scholar] [CrossRef]
  33. Schmid, M.B.; Leichsenring, M.; Keller, C.; Hegasy, G. Pancytopenia, Fever, and Splenomegaly in a 2-Year-Old Boy. Dtsch. Med. Wochenschr. 2009, 134, 1274–1277. [Google Scholar] [CrossRef]
  34. Robibaro, B.; Funk, G.C.; Dekan, G.; Demetriou, D.; Ziesche, R.; Winkler, S.; Block, L.H. Unusual Microbes in Asthma Exacerbation: Alcaligenes xylosoxidans and Leishmania. Eur. Respir. J. 2009, 33, 1216–1219. [Google Scholar] [CrossRef]
  35. Warich-Eitel, S.; Rauthe, S.; Eck, M. Gastric Leishmaniasis. A Rare Type of Gastritis. Pathologe 2010, 31, 205–207. [Google Scholar] [CrossRef]
  36. Auyeung, P.; French, M.A.; Hollingsworth, P.N. Immune Restoration Disease Associated with Leishmania donovani Infection Following Antiretroviral Therapy for HIV Infection. J. Microbiol. Immunol. Infect. 2010, 43, 74–76. [Google Scholar] [CrossRef]
  37. Ignatius, R.; Loddenkemper, C.; Woitzik, J.; Schneider, T.; Harms, G. Localized Leishmanial Lymphadenopathy: An Unusual Manifestation of Leishmaniasis in a Traveler in Southern Europe. Vector Borne Zoonotic Dis. 2011, 11, 1213–1215. [Google Scholar] [CrossRef]
  38. Moore, E.M.; Lockwood, D.N. Leishmaniasis. Clin. Med. 2011, 11, 492–497. [Google Scholar] [CrossRef]
  39. Benes, J.; Kabelková, M.; Holecková, P.; Kozák, T.; Benesová, K.; Mikulenková, D.; Nohýnková, E. Visceral Leishmaniasis (Two Case Reports). Klin. Mikrobiol. Infekc. Lek. 2012, 18, 43–47. [Google Scholar]
  40. Posch, C.; Walochnik, J.; Gschnait, A.; Feichtinger, H.; Rappersberger, K. Kala Azar-Lethal Course of Visceral Leishmaniasis. Synchronous Infection with Leishmania donovani/infantum Complex and Leishmania major in a Patient after Mediterranean Vacation. Hautarzt 2012, 63, 947–951. [Google Scholar] [CrossRef]
  41. Poeppl, W.; Herkner, H.; Tobudic, S.; Faas, A.; Auer, H.; Mooseder, G.; Burgmann, H.; Walochnik, J. Seroprevalence and Asymptomatic Carriage of Leishmania Spp. in Austria, a Non-Endemic European Country. Clin. Microbiol. Infect. 2013, 19, 572–577. [Google Scholar] [CrossRef]
  42. van Raalte, D.; Wesselius, H.; Klerk, G. Unexpected Diagnosis of Visceral Leishmaniasis in a Patient Presenting with an Infected ICD Lead. Neth. J. Med. 2014, 72, 146–148. [Google Scholar]
  43. Watkins, E.R.; Shamasunder, S.; Cascino, T.; White, K.L.; Katrak, S.; Bern, C.; Schwartz, B.S. Visceral Leishmaniasis-Associated Hemophagocytic Lymphohistiocytosis in a Traveler Returning from a Pilgrimage to the Camino de Santiago. J. Travel Med. 2014, 21, 429–432. [Google Scholar] [CrossRef]
  44. Bode, S.F.N.; Bogdan, C.; Beutel, K.; Behnisch, W.; Greiner, J.; Henning, S.; Jorch, N.; Jankofsky, M.; Jakob, M.; Schmid, I.; et al. Hemophagocytic Lymphohistiocytosis in Imported Pediatric Visceral Leishmaniasis in a Nonendemic Area. J. Pediatr. 2014, 165, 147–153. [Google Scholar] [CrossRef]
  45. Roberts, T.; Barratt, J.; Sandaradura, I.; Lee, R.; Harkness, J.; Marriott, D.; Ellis, J.; Stark, D. Molecular Epidemiology of Imported Cases of Leishmaniasis in Australia from 2008 to 2014. PLoS ONE 2015, 10, e0119212. [Google Scholar] [CrossRef]
  46. Koster, K.L.; Laws, H.J.; Troeger, A.; Meisel, R.; Borkhardt, A.; Oommen, P.T. Visceral Leishmaniasis as a Possible Reason for Pancytopenia. Front. Pediatr. 2015, 3, 59. [Google Scholar] [CrossRef]
  47. Schleenvoigt, B.T.; Ignatius, R.; Baier, M.; Schneider, T.; Weber, M.; Hagel, S.; Forstner, C.; Pletz, M.W. Development of Visceral Leishmaniasis in an HIV(+) Patient upon Immune Reconstitution Following the Initiation of Antiretroviral Therapy. Infection 2016, 44, 115–119. [Google Scholar] [CrossRef]
  48. Eichenberger, A.; Buechi, A.E.; Neumayr, A.; Hatz, C.; Rauch, A.; Huguenot, M.; Diamantis-Karamitopoulou, E.; Staehelin, C. A Severe Case of Visceral Leishmaniasis and Liposomal Amphotericin B Treatment Failure in an Immunosuppressed Patient 15 Years after Exposure. BMC Infect. Dis. 2017, 17, 81. [Google Scholar] [CrossRef]
  49. Asbury, K.; Seville, M.T.; Pritt, B.; Scotch, A.; Rosenthal, A.; Grys, T.E.; Kelemen, K. Closing the Brief Case: The Unexpected Souvenir. J. Clin. Microbiol. 2018, 56, e01414–e01417. [Google Scholar] [CrossRef]
  50. Mahendiran, T.; Doolub, G.; Nisbet, A. Fever in a Returning Traveller: Visceral Leishmaniasis Triggering Haemophagocytic Lymphohistiocytosis. BMJ Case Rep. 2018, 2018, bcr2018224775. [Google Scholar] [CrossRef]
  51. Haque, L.; Villanueva, M.; Russo, A.; Yuan, Y.; Lee, E.J.; Topal, J.; Podoltsev, N. A Rare Case of Visceral Leishmaniasis in an Immunocompetent Traveler Returning to the United States from Europe. PLoS Negl. Trop. Dis. 2018, 12, e0006727. [Google Scholar] [CrossRef]
  52. Johnson, S.M.; Gilmour, K.; Samarasinghe, S.; Bamford, A. Haemophagocytic Lymphohistiocytosis Complicating Visceral Leishmaniasis in the UK: A Case for Detailed Travel History, a High Index of Suspicion and Timely Diagnostics. BMJ Case Rep. 2019, 12, e228307. [Google Scholar] [CrossRef]
  53. Schaper, A.S.; Cremer, M.; Stackelberg, A.; Kallinich, T. Visceral Leishmaniasis in a Toddler Returning from Vacation in Southern Europe Presenting with Pancytopenia and Fever. Klin. Padiatr. 2019, 231, 269–270. [Google Scholar] [CrossRef]
  54. Blomberg, B.; Müller, K.E.; Helgeland, L.; Fladeby, C.; Mørch, K. A Man in His 80s with Arthritis and Persistent Fever. Tidsskr. Nor. Laegeforen. 2019, 139. [Google Scholar] [CrossRef]
  55. Douse, D.M.; Goldstein, R.S.; Montgomery, D.J.; Sinnott, M. Gastric Leishmaniasis in the Setting of HIV/AIDS Infection at Community Hospital in Southeastern United States. Access Microbiol. 2019, 1, e000045. [Google Scholar] [CrossRef] [PubMed]
  56. Schmutz, M.; Schaller, T.; Kubuschok, B.; Fleischmann, C.; Hirschbühl, K.; Dintner, S.; Häckel, T.; Märkl, B.; Trepel, M.; Claus, R. Periodic Fever and Pancytopenia in a 35-Year-Old Patient. Internist 2019, 60, 1305–1310. [Google Scholar] [CrossRef] [PubMed]
  57. Williams, E.; Isles, N.S.; Seemann, T.; Kilpatrick, T.; Grigg, A.; Leroi, M.; Howden, B.P.; Kwong, J.C. Case Report: Confirmation by Metagenomic Sequencing of Visceral Leishmaniasis in an Immunosuppressed Returned Traveler. Am. J. Trop. Med. Hyg. 2020, 103, 1930–1933. [Google Scholar] [CrossRef]
  58. Camilleri, M.; Richards, H.; Pomplun, S.; Wilson, A.; Checkley, A.; Rabin, N. Leishmaniasis as an Unusual Cause of Pancytopenia in a Patient Receiving Immunomodulatory Therapy for Myeloma. Br. J. Haematol. 2020, 190, 305. [Google Scholar] [CrossRef]
  59. Glans, H.; Hertting, O. Leishmaniasis a Neglected but Serious Tropical Disease. Lakartidningen 2020, 117, 19256. [Google Scholar]
  60. Offenbacher, R.; Rybinski, B.; Joseph, T.; Rahmani, N.; Boucher, T.; Weiser, D.A. An 8-Year-Old Boy With Fever, Splenomegaly, and Pancytopenia. Pediatrics 2020, 146, e20192372. [Google Scholar] [CrossRef]
  61. Aissaoui, N.; Hamane, S.; Gits-Muselli, M.; Petit, A.; Benderdouche, M.; Denis, B.; Alanio, A.; Dellière, S.; Bagot, M.; Bretagne, S. Imported Leishmaniasis in Travelers: A 7-Year Retrospective from a Parisian Hospital in France. BMC Infect. Dis. 2021, 21, 953. [Google Scholar] [CrossRef]
  62. Schwetz, V.; Trummer, C.; Friedl, C.; Beham-Schmid, C.; Kulnik, R.; Wölfler, A.; Horvath, K.; Wunsch, S.; Prattes, J.; Zollner-Schwetz, I.; et al. Visceral Leishmaniasis in a Patient with Diabetes Mellitus Type 2 and Discrete Bicytopenia. Clin. Case Rep. 2017, 6, 78–81. [Google Scholar] [CrossRef]
  63. Lübbert, C.; Opitz, B.M.; Harms-Zwingenberger, G.; Nietsch, H.H. Fever, Pancytopenia, and Splenomegaly 8 Months after a Trip to Majorca Island (Spain). Med. Klin 2008, 103, 29–35. [Google Scholar] [CrossRef]
  64. Hamilton, A.; Kelleher, A.; Marriott, D. A Case of Severe Visceral Leishmaniasis Resulting from Travel to Greece. BMJ Case Rep. 2009, 2009, bcr06.2009.2036. [Google Scholar] [CrossRef]
  65. Herremans, T.; Pinelli, E.; Casparie, M.; Nozari, N.; Roelfsema, J.; Kortbeek, L. Increase of Imported Leishmaniasis in the Netherlands: A Twelve Year Overview (1996–2007). Int. Health 2010, 2, 42–46. [Google Scholar] [CrossRef]
  66. Schwartz, T.; Jensenius, M.; Blomberg, B.; Fladeby, C.; Mæland, A.; Pettersen, F.O. Imported Visceral Leishmaniasis and Immunosuppression in Seven Norwegian Patients. Trop. Dis. Travel Med. Vaccines 2019, 5, 16. [Google Scholar] [CrossRef]
  67. Tzani, M.; Barrasa, A.; Vakali, A.; Georgakopoulou, T.; Mellou, K.; Pervanidou, D. Surveillance Data for Human Leishmaniasis Indicate the Need for a Sustainable Action Plan for Its Management and Control, Greece, 2004 to 2018. Euro. Surveill. 2021, 26, 2000159. [Google Scholar] [CrossRef]
  68. Dujardin, A.; de La Blanchardière, A.; Dina, J.; Stefic, K.; Ravel, C.; Bonhomme, J.; Verdon, R.; Fournier, A.L. Case Report: Leishmania and HIV Co-Diagnosis: How to Understand Medical History? Front. Immunol. 2021, 12, 669723. [Google Scholar] [CrossRef]
  69. Tan, H.H.; Wong, S.S.; Ong, B.H. Cutaneous Leishmaniasis: A Report of Two Cases Seen at a Tertiary Dermatological Centre in Singapore. Singap. Med. J. 2000, 41, 179–181. [Google Scholar]
  70. Brecelj, M.; Pikelj, F.; Gubenšek, F.; Anderluh, G. Polymerase Chain Reaction as a Diagnostic Tool for Detecting Leishmania. Infection 2000, 28, 111–113. [Google Scholar] [CrossRef]
  71. Manfredi, R.; di Bari, M.A.; Calza, L.; Chiodo, F. American Cutaneous Leishmaniasis as a Rare Imported Disease in Europe: A Case Report Favourably Treated with Antimonial Derivatives. Eur. J. Epidemiol. 2001, 17, 793–795. [Google Scholar] [CrossRef]
  72. Sotiropoulos, G.; Wilbur, B. Two Cases of Cutaneous Leishmaniasis Presenting to the Emergency Department as Chronic Ulcers. J. Emerg. Med. 2001, 20, 353–356. [Google Scholar] [CrossRef]
  73. Mackowiak, P.A.; Hatchette, T.F.; Green, P.; Schlech, W.F.; Haase, D.A.; Miller, R.; Haldane, D.J.M. Lesion on the Arm of a Returning Traveler. Cutaneous Leishmaniasis. Clin. Infect. Dis. 2001, 33, 815. [Google Scholar] [CrossRef]
  74. Galioto, P.; Fornaro, V. A Case of Mucocutaneous Leishmaniasis. Ear. Nose. Throat J. 2002, 81, 46–48. [Google Scholar] [CrossRef]
  75. Scope, A.; Trau, H.; Anders, G.; Barzilai, A.; Confino, Y.; Schwartz, E. Experience with New World Cutaneous Leishmaniasis in Travelers. J. Am. Acad. Dermatol. 2003, 49, 672–678. [Google Scholar] [CrossRef]
  76. Scope, A.; Trau, H.; Bakon, M.; Yarom, N.; Nasereddin, A.; Schwartz, E. Imported Mucosal Leishmaniasis in a Traveler. Clin. Infect. Dis. 2003, 37, 83–87. [Google Scholar] [CrossRef]
  77. Lawn, S.D.; Yardley, V.; Vega-Lopez, F.; Watson, J.; Lockwood, D.N. New World Cutaneous Leishmaniasis in Returned Travellers: Treatment Failures Using Intravenous Sodium Stibogluconate. Trans. R. Soc. Trop. Med. Hyg. 2003, 97, 443–445. [Google Scholar] [CrossRef]
  78. Haider, S.; Boutross-Tadross, O.; Radhi, J.; Momar, N. Cutaneous Ulcer in a Man Returning from Central America. CMAJ 2003, 4, 591. [Google Scholar]
  79. Bormann, G.; William, T.; Schulz, A.; Marsch, W.; Gaber, G. American Cutaneous Leishmaniasis: Special Features in Diagnosis and Therapy. Dtsch. Med. Wochenschr. 2003, 128, 2065–2068. [Google Scholar] [CrossRef]
  80. Costa, J.W.; Milner, D.A.; Maguire, J.H. Mucocutaneous Leishmaniasis in a US Citizen. Oral. Sur.g Oral. Med. Oral. Pathol. Oral. Radiol. Endod. 2003, 96, 573–577. [Google Scholar] [CrossRef]
  81. el Hajj, L.; Thellier, M.; Carrière, J.; Bricaire, F.; Danis, M.; Caumes, E. Localized Cutaneous Leishmaniasis Imported into Paris: A Review of 39 Cases. Int. J. Dermatol. 2004, 43, 120–125. [Google Scholar] [CrossRef]
  82. Lawn, S.D.; Whetham, J.; Chiodini, P.L.; Kanagalingam, J.; Watson, J.; Behrens, R.H.; Lockwood, D.N.J. New World Mucosal and Cutaneous Leishmaniasis: An Emerging Health Problem among British Travellers. QJM 2004, 97, 781–788. [Google Scholar] [CrossRef]
  83. Morelli, P.; Gianelli, E.; Calattini, S.; Corbellino, M.; Antinori, S.; Meroni, L. Itraconazole Can Be Effective in the Treatment of Sporotrichoid Leishmaniasis. J. Travel Med. 2004, 11, 328–330. [Google Scholar] [CrossRef]
  84. Cardenas, G.A.; Gonzalez-Serva, A.; Cohen, C. Multiple Leg Ulcers in a Traveler. Cleve Clin. J. Med. 2004, 71, 109–112. [Google Scholar] [CrossRef] [PubMed]
  85. Storer, E.; Wayte, J. Cutaneous Leishmaniasis in Afghani Refugees. Australas. J. Derm. 2005, 46, 80–83. [Google Scholar] [CrossRef] [PubMed]
  86. Raschke, A.; Wetzig, T.; Paasch, U.; Grunewald, S.; Simon, J.C. Firm Blue-Red Solid Nodules on the Forehead of a 39-Year-Old Patient. J. Dtsch. Dermatol. Ges. 2005, 3, 919–920. [Google Scholar] [CrossRef] [PubMed]
  87. Loo, W.J.; Chan, S.K.; Rytina, E.; Lockwoood, D.N.J.; Sterling, J.C.; Todd, P. Five Cases of Cutaneous Leishmaniasis in Cambridge, U.K. Br. J. Dermatol. 2005, 153, 1076–1078. [Google Scholar] [CrossRef]
  88. Antonovich, D.D.; Callen, J.P.; Paniker, P.U. No Walk in the Park. Am. J. Med. 2005, 118, 715–716. [Google Scholar] [CrossRef]
  89. Mateo, M.; Cruz, I.; Flores, M.D.; López-Vélez, R. Slowly Progressing Skin Ulcers Following a Stay in Costa Rica. Enferm. Infecc. Y Microbiol. Clin. 2005, 23, 243–244. [Google Scholar] [CrossRef]
  90. Zeegelaar, J.E.; Steketee, W.H.; van Thiel, P.P.A.M.; Wetsteyn, J.C.F.M.; Kager, P.A.; Faber, W.R. Changing Pattern of Imported Cutaneous Leishmaniasis in the Netherlands. Clin. Exp. Dermatol. 2005, 30, 1–5. [Google Scholar] [CrossRef]
  91. Scarisbrick, J.J.; Chiodini, P.L.; Watson, J.; Moody, A.; Armstrong, M.; Lockwood, D.; Bryceson, A.; Vega-López, F. Clinical Features and Diagnosis of 42 Travellers with Cutaneous Leishmaniasis. Travel Med. Infect. Dis. 2006, 4, 14–21. [Google Scholar] [CrossRef]
  92. Vinetz, J.M.; Soong, L. Leishmania Mexicana Infection of the Eyelid in a Traveler to Belize. Braz. J. Infect. Dis. 2007, 11, 149–152. [Google Scholar] [CrossRef]
  93. Ismailjee, S.B.; Bernstein, J.M.; Burdette, S.D. Bite the Hand That Sprays You. Skinmed 2006, 5, 296–299. [Google Scholar] [CrossRef]
  94. Ather, S.; Chan, D.S.; Leaper, D.J.; Harding, K.G. Case Report and Literature Review of Leishmaniasis as a Cause of Leg Ulceration in the United Kingdom. J. Wound Care 2006, 15, 389–391. [Google Scholar] [CrossRef]
  95. Morizot, G.; Delgiudice, P.; Caumes, E.; Laffitte, E.; Marty, P.; Dupuy, A.; Sarfati, C.; Hadj-Rabia, S.; Darie, H.; le Guern, A.S.; et al. Healing of Old World Cutaneous Leishmaniasis in Travelers Treated with Fluconazole: Drug Effect or Spontaneous Evolution? Am. J. Trop. Med. Hyg. 2007, 76, 48–52. [Google Scholar] [CrossRef]
  96. Schnedl, J.; Auer, H.; Fischer, M.; Tomaso, H.; Pustelnik, T.; Mooseder, G. Cutaneous Leishmaniasis—An Import from Belize. Wien. Klin. Wochenschr. 2007, 119, 102–105. [Google Scholar] [CrossRef]
  97. Campos-Muñoz, L.; Quesada-Cortés, A.; Martín-Díaz, M.A.; Rubio-Flores, C.; de Lucas-Laguna, R. Leishmania braziliensis: Report of a Pediatric Imported Case With Response to Liposomal Amphotericin B. Actas Dermosifiliogr. 2007, 98, 42–44. [Google Scholar] [CrossRef]
  98. Konecny, P.; Stark, D.J. An Australian Case of New World Cutaneous Leishmaniasis. Med. J. Aust. 2007, 186, 315–317. [Google Scholar] [CrossRef]
  99. González-Llavona, B.; Biosca-Echenique, G.; Soto-Díaz, A.; Naranjo-Díaz, M.J.; Espadafor-López, B.; García-Mellado, V. Cutaneous Leishmaniasis in a Senegal Patient. Actas Dermo. Sifiliogr. 2007, 98, 54–58. [Google Scholar] [CrossRef]
  100. Solomon, M.; Baum, S.; Barzilai, A.; Scope, A.; Trau, H.; Schwartz, E. Liposomal Amphotericin B in Comparison to Sodium Stibogluconate for Cutaneous Infection Due to Leishmania braziliensis. J. Am. Acad. Dermatol. 2007, 56, 612–616. [Google Scholar] [CrossRef]
  101. Delgado, O.; Silva, S.; Coraspe, V.; Rivas, M.A.; Rodriguez-Morales, A.J.; Navarro, P.; Franco-Paredes, C. Cutaneous Leishmaniasis Imported from Colombia to Northcentral Venezuela: Implications for Travel Advice. Travel Med. Infect. Dis. 2008, 6, 376–379. [Google Scholar] [CrossRef]
  102. Schleucher, R.D.; Zanger, P.; Gaessler, M.; Knobloch, J. Successful Diagnosis and Treatment 50 Years after Exposure: Is Mucocutaneous Leishmaniasis Still a Neglected Differential Diagnosis? J. Travel Med. 2008, 15, 466–467. [Google Scholar] [CrossRef]
  103. Ahmed, Z.; Chowdhury, S.; Bhuiyan, S. Cutaneous Leishmaniasis. Mymensingh Med. J. 2009, 18, 260–263. [Google Scholar]
  104. Berens-Riha, N.; Fleischmann, E.; Pratlong, F.; Bretzel, G.; von Sonnenburg, F.; Löscher, T. Cutaneous Leishmaniasis (Leishmania tropica) in a German Tourist after Travel to Greece. J. Travel Med. 2009, 16, 220–222. [Google Scholar] [CrossRef]
  105. Holmes, W.J.M.; Tehrani, H.; Liew, S. Cutaneous Leishmaniasis: A Diagnosis of Suspicion. J. Hand Surg. Eur. Vol. 2009, 34, 555–556. [Google Scholar] [CrossRef]
  106. van der Snoek, E.M.; Lammers, A.M.; Kortbeek, L.M.; Roelfsema, J.H.; Bart, A.; Jaspers, C.A.J.J. Spontaneous Cure of American Cutaneous Leishmaniasis Due to Leishmania naiffi in Two Dutch Infantry Soldiers. Clin. Exp. Dermatol. 2009, 34, e889–91. [Google Scholar] [CrossRef]
  107. González, M.; Benito, F.; García, L.; Iglesias, A. Mucocutaneous Leishmaniasis: An Imported Illness with ENT Repercussions. Acta Otorrinolaringol. Esp. 2009, 60, 298–300. [Google Scholar] [CrossRef]
  108. Jeddi, F.; Caumes, E.; Thellier, M.; Jauréguiberry, S.; Mazier, D.; Buffet, P.A. Drug Hypersensitivity Syndrome Induced by Meglumine Antimoniate. Am. J. Trop. Med. Hyg. 2009, 80, 939–940. [Google Scholar] [CrossRef]
  109. Santangeli, L.; McCluney, N.A.; Hathorn, I.; Shakeel, M.; Anderson, C. Leishmaniasis Presenting to the Otolaryngologist: A Rare but Important Cause of Persistent Hoarseness. J. Laryngol. Otol. 2009, 123, 1181–1183. [Google Scholar] [CrossRef]
  110. Mulvaney, P.; Aram, G.; Maggiore, P.R.; Kutzner, H.; Carlson, J.A. Delay in Diagnosis: Trauma-and Coinfection-Related Cutaneous Leishmaniasis Because of Leishmania guyanensis Infection. J. Cutan. Pathol. 2009, 36, 53–60. [Google Scholar] [CrossRef]
  111. Leitner, V.; Weingast, J.; Harmankaya, K.; Walochnik, J.; Pehamberger, H.; Petzelbauer, P.; Auer, H.; Binder, M. Leishmaniasis in the Tongue of an Immunocompetent Man. Am. J. Trop. Med. Hyg. 2010, 82, 597–599. [Google Scholar] [CrossRef] [PubMed]
  112. van Thiel, P.P.A.M.; Leenstra, T.; Kager, P.A.; de Vries, H.J.; van Vugt, M.; van der Meide, W.F.; Bart, A.; Zeegelaar, J.E.; van der Sluis, A.; Schallig, H.D.F.H.; et al. Miltefosine Treatment of Leishmania major Infection: An Observational Study Involving Dutch Military Personnel Returning from Northern Afghanistan. Clin. Infect. Dis. 2010, 50, 80–83. [Google Scholar] [CrossRef] [PubMed]
  113. Marovt, M.; Kokol, R.; Stanimirović, A.; Miljković, J. Cutaneous Leishmaniasis: A Case Report. Acta Dermatovenerol. Alp. Pannonica. Adriat. 2010, 19, 41–43. [Google Scholar] [PubMed]
  114. Mazumder, S.A.; Pandey, S.; Brewer, S.C.; Baselski, V.S.; Weina, P.J.; Land, M.A.; Fleckenstein, J.M. Lingual Leishmaniasis Complicating Visceral Disease. J. Travel Med. 2010, 17, 212–214. [Google Scholar] [CrossRef]
  115. Crogan, J.; Gunasekera, H.; Wood, N.; Sheikh, M.; Isaacs, D. Management of Old World Cutaneous Leishmaniasis in Refugee Children. Pediatr. Infect. Dis. J. 2010, 29, 357–359. [Google Scholar] [CrossRef]
  116. Harms, G.; Scherbaum, H.; Reiter-Owona, I.; Stich, A.; Richter, J. Treatment of Imported New World Cutaneous Leishmaniasis in Germany. Int. J. Dermatol. 2011, 50, 1336–1342. [Google Scholar] [CrossRef]
  117. Cannella, A.P.; Nguyen, B.M.; Piggott, C.D.; Lee, R.A.; Vinetz, J.M.; Mehta, S.R. A Cluster of Cutaneous Leishmaniasis Associated with Human Smuggling. Am. J. Trop. Med. Hyg. 2011, 84, 847–850. [Google Scholar] [CrossRef]
  118. Solomon, M.; Benenson, S.; Baum, S.; Schwartz, E. Tropical Skin Infections among Israeli Travelers. Am. J. Trop. Med. Hyg. 2011, 85, 868–872. [Google Scholar] [CrossRef]
  119. Zanger, P.; Kötter, I.; Raible, A.; Gelanew, T.; Schönian, G.; Kremsner, P.G. Case Report: Successful Treatment of Cutaneous Leishmaniasis Caused by Leishmania aethiopica with Liposomal Amphothericin B in an Immunocompromised Traveler Returning from Eritrea. Am. J. Trop. Med. Hyg. 2011, 84, 692–694. [Google Scholar] [CrossRef]
  120. Zaghi, D.; Panosian, C.; Gutierrez, M.A.; Gregson, A.; Taylor, E.; Ochoa, M.T. New World Cutaneous Leishmaniasis: Current Challenges in Diagnosis and Parenteral Treatment. J. Am. Acad. Dermatol. 2011, 64, 587–592. [Google Scholar] [CrossRef]
  121. Mougin, B.; Avenel-Audran, M.; Hasseine, L.; Martin, L.; Cottin, J.; Pomares, C.; Delaunay, P.; Marty, P.; Ravel, C.; Chabasse, D.; et al. A Cutaneous Ulcer Resulting from Mycobacterium ulcerans–Leishmania braziliensis Coinfection in South America. Am. J. Trop. Med. Hyg. 2011, 85, 897–899. [Google Scholar] [CrossRef]
  122. Blaylock, J.M.; Wortmann, G.W. A Case Report and Literature Review of “Chiclero’s Ulcer”. Travel Med. Infect. Dis. 2012, 10, 275–278. [Google Scholar] [CrossRef]
  123. Kelly, P.; Baudry, T.; Peyron, F. Imported Cutaneous Leishmaniasis in a Short-Term Traveler Returning from Central Mali-The Role of PCR. Travel Med. Infect. Dis. 2012, 10, 97–100. [Google Scholar] [CrossRef]
  124. Terhorst, D.; Blume-Peytavi, U.; Schönian, G.; Schewe, C.; Haas, N.; Burbach, G.J. Leishmaniasis: A Reminder in the Face of Forgotten Travel. J. Pediatr. 2012, 161, 966. [Google Scholar] [CrossRef]
  125. Wise, E.S.; Armstrong, M.S.; Watson, J.; Lockwood, D.N. Monitoring Toxicity Associated with Parenteral Sodium Stibogluconate in the Day-Case Management of Returned Travellers with New World Cutaneous Leishmaniasis. PLoS Negl. Trop. Dis. 2012, 6, e1688. [Google Scholar] [CrossRef]
  126. Poeppl, W.; Oeser, C.; Grabmeier-Pfistershammer, K.; Walochnik, J.; Burgmann, H. Clinical Findings and Management of Imported Cutaneous Leishmaniasis: Report of 14 Cases from Austria. Travel Med. Infect. Dis. 2013, 11, 90–94. [Google Scholar] [CrossRef]
  127. Fathi, R.; Fathi, A. A Case of Cutaneous Leishmaniasis Found in Indiana. Derm. Online J. 2013, 19, 18982. [Google Scholar] [CrossRef]
  128. Demers, E.; Forrest, D.M.; Weichert, G.E. Cutaneous Leishmaniasis in a Returning Traveller. CMAJ 2013, 185, 681–683. [Google Scholar] [CrossRef]
  129. Eichner, S.; Thoma-Uszynski, S.; Herrgott, I.; Sebald, H.; Debus, A.; Tsianakas, A.; Ehrchen, J.; Harms, G.; Simon, M.; Sunderkötter, C.; et al. Clinical Complexity of Leishmania (Viannia) braziliensis Infections amongst Travelers. Eur. J. Derm. 2013, 23, 218–223. [Google Scholar] [CrossRef]
  130. Teemul, T.A.; Giles-Lima, M.; Williams, J.; Lester, S.E. Laryngeal Leishmaniasis: Case Report of a Rare Infection. Head Neck 2013, 35, E277–E279. [Google Scholar] [CrossRef]
  131. Veraldi, S.; Tavecchio, S. Gifts from the Tropics. Int. J. Derm. 2013, 52, 896–897. [Google Scholar] [CrossRef]
  132. Neumayr, A.L.C.; Morizot, G.; Visser, L.G.; Lockwood, D.N.J.; Beck, B.R.; Schneider, S.; Bellaud, G.; Cordoliani, F.; Foulet, F.; Laffitte, E.A.; et al. Clinical Aspects and Management of Cutaneous Leishmaniasis in Rheumatoid Patients Treated with TNF-α Antagonists. Travel Med. Infect. Dis. 2013, 11, 412–420. [Google Scholar] [CrossRef] [PubMed]
  133. Mosimann, V.; Neumayr, A.; Hatz, C.; Blum, J.A. Cutaneous Leishmaniasis in Switzerland: First Experience with Species-Specific Treatment. Infection 2013, 41, 1177–1182. [Google Scholar] [CrossRef] [PubMed]
  134. Larréché, S.; Launay, G.; Weibel Galluzzo, C.; Bousquet, A.; Eperon, G.; Pilo, J.E.; Ravel, C.; Chappuis, F.; Dupin, M.; Mérens, A. Cluster of Zoonotic Cutaneous Leishmaniasis (Leishmania major) in European Travelers Returning from Turkmenistan. J. Travel Med. 2013, 20, 400–402. [Google Scholar] [CrossRef] [PubMed]
  135. Ehlert, N.; Seilmaier, M.; Guggemos, W.; Löscher, T.; Meurer, A.; Wendtner, C.M. Severe Oral Mucositis in a Patient with HIV Infection. Dtsch. Med. Wochenschr. 2013, 138, 1601–1605. [Google Scholar] [CrossRef] [PubMed]
  136. Lavergne, R.A.; Iriart, X.; Martin-Blondel, G.; Chauvin, P.; Menard, S.; Fillaux, J.; Cassaing, S.; Roques-Malecaze, C.; Arnaud, S.; Valentin, A.; et al. Contribution of Molecular Diagnosis to the Management of Cutaneous Leishmaniasis in Travellers. Clin. Microbiol. Infect. 2014, 20, O528–O530. [Google Scholar] [CrossRef]
  137. van Hees, C.; van Hellemond, J.; den Boer, M. A Boy with an Unexpected Souvenir from Morocco. Ned. Tijdschr. Voor Geneeskd. 2014, 158, A7606. [Google Scholar]
  138. Ntais, P.; Christodoulou, V.; Tsirigotakis, N.; Dokianakis, E.; Dedet, J.P.; Pratlong, F.; Antoniou, M. Will the Introduction of Leishmania tropica MON-58, in the Island of Crete, Lead to the Settlement and Spread of This Rare Zymodeme? Acta Trop. 2014, 132, 125–130. [Google Scholar] [CrossRef]
  139. Barry, M.A.; Koshelev, M.V.; Sun, G.S.; Grekin, S.J.; Stager, C.E.; Diwan, A.H.; Wasko, C.A.; Murray, K.O.; Woc-Colburn, L. Cutaneous Leishmaniasis in Cuban Immigrants to Texas Who Traveled through the Darién Jungle, Panama. Am. J. Trop. Med Hyg. 2014, 91, 345–347. [Google Scholar] [CrossRef]
  140. Raghunath, R.S.; Yong, A.S.W.; Igali, L.; Tan, E.; Lockwood, D. Cutaneous Leishmaniasis in a Returning UK Traveller. Postgrad. Med. J. 2014, 90, 540–541. [Google Scholar] [CrossRef]
  141. Trufant, J.; Lewin, J.; Christopher, H.; Meehan, S.; Pomeranz, M. New World Cutaneous Leishmaniasis. Derm. Online J. 2014, 20, 13030. [Google Scholar] [CrossRef]
  142. Downing, C.P.; Woc-Colburn, L.; Tyring, S.K. Nasal Erythema and Crusting after a Trip to the Venezuelan Rainforest. JAMA 2014, 312, 1250–1251. [Google Scholar] [CrossRef]
  143. Siah, T.; Lavender, T.; Charlton, F.; Wahie, S.; Schwab, U. An Unusual Erysipelas-like Presentation. Derm. Online J. 2014, 20, 21255. [Google Scholar] [CrossRef]
  144. Ito, K.; Takahara, M.; Ito, M.; Oshiro, M.; Takahashi, K.; Uezato, H.; Imafuku, S. An Imported Case of Cutaneous Leishmaniasis Caused by Leishmania (Leishmania) donovani in Japan. J. Dermatol. 2014, 41, 926–928. [Google Scholar] [CrossRef]
  145. Rahman, H.; Razzak, M.; Chanda, B.; Bhaskar, K.; Mondal, D. Cutaneous Leishmaniasis in an Immigrant Saudi Worker: A Case Report. J. Health Popul. Nutr. 2014, 32, 372–376. [Google Scholar]
  146. Nadler, C.; Enk, C.D.; Leon, G.T.; Samuni, Y.; Maly, A.; Czerninski, R. Diagnosis and Management of Oral Leishmaniasis—Case Series and Literature Review. J. Oral. Maxillofac. Surg. 2014, 72, 927–934. [Google Scholar] [CrossRef]
  147. Bailey, M.S.; Langman, G. Misdiagnosis of Cutaneous Leishmaniasis and Recurrence after Surgical Excision. J. R Army Med. Corps 2014, 160, 314–316. [Google Scholar] [CrossRef]
  148. Calderaro, A.; Montecchini, S.; Rossi, S.; Gorrini, C.; Dell’Anna, M.L.; Piccolo, G.; Medici, M.C.; Arcangeletti, M.C.; Chezzi, C.; de Conto, F. A 22-Year Survey of Leishmaniasis Cases in a Tertiary-Care Hospital in an Endemic Setting. Int. J. Environ. Res. Public Health 2014, 11, 2834–2845. [Google Scholar] [CrossRef]
  149. Tan, E.M.; Marcelin, J.R.; Virk, A. Photo Quiz: A 24-Year-Old Traveler with an Insect Bite and Rash. Clin. Infect. Dis. 2015, 61, 1314. [Google Scholar] [CrossRef]
  150. Cohen, J.; Saavedra, A.; Sax, P.; Lipworth, A. Pink Plaque on the Arm of a Man after a Trip to Mexico: Cutaneous Leishmaniasis. Dermatol. Online J. 2015, 21, 13030. [Google Scholar] [CrossRef]
  151. Vanbrabant, P.; van den Broucke, S.; Soentjens, P. Cutaneous Ulcer after a Stay in the Tropics. Neth. J. Med. 2015, 73, 44. [Google Scholar]
  152. Wollina, U.; Koch, A.; Schönlebe, J.; Tchernev, G.; Chokoeva, A.; Lotti, T. Non-Healing Facial Lesions: Cutaneous Old World Leishmaniasis in Dresden. J. Biol. Regul. Homeost. Agents 2015, 29, 99–102. [Google Scholar]
  153. Menten, K.; Soentjens, P.; Caenepeel, P.; Lemkens, P. Mucocutaneous Leishmaniasis of the Nose: A Case Report. B-ENT 2015, 11, 77–80. [Google Scholar]
  154. Crovetto-Martínez, R.; Aguirre-Urizar, J.M.; Orte-Aldea, C.; Araluce-Iturbe, I.; Whyte-Orozco, J.; Crovetto-De La Torre, M.A. Mucocutaneous Leishmaniasis Must Be Included in the Differential Diagnosis of Midline Destructive Disease: Two Case Reports. Oral. Surg. Oral. Med. Oral. Pathol. Oral. Radiol. 2015, 119, e20–e26. [Google Scholar] [CrossRef] [PubMed]
  155. Roberts, R.M.; Mukherjee, J.; Phillips, D. Laryngeal Leishmaniasis in a Patient Taking Inhaled Corticosteroids. BMJ Case Rep. 2016, 2016, bcr2016215444. [Google Scholar] [CrossRef] [PubMed]
  156. Zhang, M.; Liu, F.; Liu, H.B.; Hu, W.X.; Sang, H. Imported Cutaneous Leishmaniasis Caused by Leishmania major in a Chinese Laborer Who Worked in Saudi Arabia. An. Bras. Dermatol. 2016, 91, 365–367. [Google Scholar] [CrossRef]
  157. Bradshaw, S.; Litvinov, I.V. Dermal Leishmaniasis in a 25-Year-Old Syrian Refugee. CMAJ 2017, 189, E1397. [Google Scholar] [CrossRef]
  158. Patel, T.A.; Scadding, G.K.; Phillips, D.E.; Lockwood, D.N. Case Report: Old World Mucosal Leishmaniasis: Report of Five Imported Cases to the Hospital for Tropical Diseases, London, United Kingdom. Am. J. Trop. Med. Hyg. 2017, 97, 1116–1119. [Google Scholar] [CrossRef]
  159. Goodrich, E.S.; Sears, S.C.; Sorrells, T.; Radike, J.K.; Miladi, A.; Glass, J.S. A Case of Cutaneous Leishmaniasis guyanensis Mimicking Otitis Externa. Mil. Med. 2017, 182, e1969–e1972. [Google Scholar] [CrossRef]
  160. Basher, A.; Nath, P.; Dey, T.; Sayeed, A.A.; Faiz, M.A.; Chowdhury, F.R. Cutaneous Leishmaniasis in Immigrant Workers Returning to Bangladesh—An Emerging Problem. Travel Med. Infect. Dis. 2017, 19, 62–63. [Google Scholar] [CrossRef]
  161. Harrison, N.; Walochnik, J.; Ramsebner, R.; Veletzky, L.; Lagler, H.; Ramharter, M. Case Report: Progressive Perforation of the Nasal Septum Due to Leishmania major: A Case of Mucosal Leishmaniasis in a Traveler. Am. J. Trop. Med. Hyg. 2017, 96, 653–655. [Google Scholar] [CrossRef]
  162. van der Snoek, E.M.; Couwenberg, S.M.; Stijnis, C.; Kortbeek, L.M.; Schadd, E.M. Two Cases of Cutaneous Leishmaniasis in Dutch Military Personnel Treated with Oral Miltefosine. J. R Army Med. Corps 2017, 163, 68–70. [Google Scholar] [CrossRef]
  163. Challener, D.; Abu Saleh, O. A Traveler’s Unwanted Souvenir. Am. J. Med. 2018, 131, e137–e138. [Google Scholar] [CrossRef]
  164. Knöpfel, N.; Noguera-Morel, L.; Azorin, D.; Sanz, F.; Torrelo, A.; Hernández-Martín, A. Cutaneous Leishmania Tropica in Children: Report of Three Imported Cases Successfully Treated with Liposomal Amphotericin B. J. Eur. Acad. Dermatol. Venereol. 2018, 32, e8–e10. [Google Scholar] [CrossRef] [PubMed]
  165. Clegg, A.; Hall, C.; Lockwood, D. An Ulcer That Will Not Heal. BMJ 2018, 362, k3042. [Google Scholar] [CrossRef] [PubMed]
  166. Montalvo, A.M.; Fraga, J.; Blanco, O.; González, D.; Monzote, L.; Soong, L.; Capó, V. Imported Leishmaniasis Cases in Cuba (2006–2016): What Have We Learned. Trop. Dis. Travel Med. Vaccines 2018, 4, 7. [Google Scholar] [CrossRef]
  167. Imai, K.; Tarumoto, N.; Amo, K.; Takahashi, M.; Sakamoto, N.; Kosaka, A.; Kato, Y.; Mikita, K.; Sakai, J.; Murakami, T.; et al. Non-Invasive Diagnosis of Cutaneous Leishmaniasis by the Direct Boil Loop-Mediated Isothermal Amplification Method and MinIONTM Nanopore Sequencing. Parasitol. Int. 2018, 67, 34–37. [Google Scholar] [CrossRef]
  168. Islam, S. Rapidly Progressing Facial Leishmaniasis: Effective Treatment with Liposomal Amphotericin B and a Review of the Management of Old World Cutaneous Leishmaniasis. Paediatr. Int. Child Health 2018, 38, 158–161. [Google Scholar] [CrossRef]
  169. Michelerio, A.; Barruscotti, S.; Bossi, G.; Brazzelli, V. Pediatric Old World Cutaneous Leishmaniasis Treated with Oral Fluconazole: A Case Series. Pediatr. Dermatol. 2018, 35, 384–387. [Google Scholar] [CrossRef]
  170. Navarrete-Dechent, C.; Cevallos, C.; Jercic, M.I.; Saldias-Fuentes, C.; González, S.; Labarca, J. Liposomal Amphotericin B Treatment of Cutaneous Leishmaniasis Caused by L. braziliensis: An Imported Case Report. Rev. Chil. Infectol. 2018, 35, 612–616. [Google Scholar] [CrossRef]
  171. Imessaoudene, L.; Jacobs, C.; Hunt, W. Cutaneous Leishmaniasis in a Globetrotting Explorer. BMJ Case Rep. 2019, 12. [Google Scholar] [CrossRef]
  172. Hijawi, K.J.F.; Hijjawi, N.S.; Ibbini, J.H. Detection, Genotyping, and Phylogenetic Analysis of Leishmania Isolates Collected from Infected Jordanian Residents and Syrian Refugees Who Suffered from Cutaneous Leishmaniasis. Parasitol. Res. 2019, 118, 793–805. [Google Scholar] [CrossRef]
  173. Solomon, M.; Sahar, N.; Pavlotzky, F.; Barzilai, A.; Jaffe, C.L.; Nasereddin, A.; Schwartz, E. Mucosal Leishmaniasis in Travelers with Leishmania braziliensis Complex Returning to Israel. Emerg. Infect. Dis. 2019, 25, 642–648. [Google Scholar] [CrossRef]
  174. Khan, M.A.A.; Chowdhury, R.; Nath, R.; Hansen, S.; Nath, P.; Maruf, S.; Abd El Wahed, A.; Mondal, D. Imported Cutaneous Leishmaniasis: Molecular Investigation Unveils Leishmania major in Bangladesh. Parasit Vectors 2019, 12. [Google Scholar] [CrossRef]
  175. Taxy, J.B.; Goldin, H.M.; Dickie, S.; Cibull, T. Cutaneous Leishmaniasis: Contribution of Routine Histopathology in Unexpected Encounters. Am. J. Surg. Pathol. 2019, 43, 195–200. [Google Scholar] [CrossRef]
  176. Fernández-Figueroa, E.A.; Sánchez-Montes, S.; Miranda-Ortíz, H.; Mendoza-Vargas, A.; Cervantes-Sarabia, R.; Cárdenas-Ovando, R.A.; Ruiz-Remigio, A.; Becker, I. Relevance of Epidemiological Surveillance in Travelers: An Imported Case of Leishmania tropica in Mexico. Rev. Inst. Med. Trop. S. Paulo 2020, 62, 1–5. [Google Scholar] [CrossRef]
  177. Crone, C.G.; Helleberg, M. Cutaneous Leishmaniasis with Secondary Mucosal Disease in a Traveller Due to Leishmania (Viannia) braziliensis. J. Travel Med. 2020, 27. [Google Scholar] [CrossRef]
  178. Mann, S.; Phupitakphol, T.; Davis, B.; Newman, S.; Suarez, J.A.; Henao-Martínez, A.; Franco-Paredes, C. Case Report: Cutaneous Leishmaniasis Due to Leishmania (Viannia) panamensis in Two Travelers Successfully Treated with Miltefosine. Am. J. Trop. Med. Hyg. 2020, 103, 1081–1084. [Google Scholar] [CrossRef]
  179. Basile, G.; Cristofaro, G.; Locatello, L.G.; Vellere, I.; Piccica, M.; Bresci, S.; Maggiore, G.; Gallo, O.; Novelli, A.; di Muccio, T.; et al. Refractory Mucocutaneous Leishmaniasis Resolved with Combination Treatment Based on Intravenous Pentamidine, Oral Azole, Aerosolized Liposomal Amphotericin B, and Intralesional Meglumine Antimoniate. Int. J. Infect. Dis. 2020, 97, 204–207. [Google Scholar] [CrossRef]
  180. Murray, H.W.; Eiras, D.P.; Kirkman, L.A.; Chai, R.L.; Caplivski, D. Case Report: Mucosal Leishmaniasis in New York City. Am. J. Trop. Med. Hyg. 2020, 102, 1319–1322. [Google Scholar] [CrossRef]
  181. Talas, J.; Mielcarek, K.; Wu, J.; Brunner, M.; Steinhoff, M.; Zouboulis, C.C. Cutaneous Leishmaniasis in Germany-Still a Travel-Related Disease. Der Hautarzt Z. Fur Dermatol. Venerol. Und Verwandte Geb. 2022, 73, 146–151. [Google Scholar] [CrossRef]
  182. Abadir, A.; Patel, A.; Haider, S. Systemic Therapy of New World Cutaneous Leishmaniasis: A Case Report and Review Article. Can. J. Infect. Dis. Med Microbio.l 2010, 21, e79–e83. [Google Scholar] [CrossRef]
  183. Madke, B.; Kharkar, V.; Chikhalkar, S.; Mahajan, S.; Khopkar, U. Successful Treatment of Multifocal Cutaneous Leishmaniasis with Miltefosine. Indian J. Dermatol. 2011, 56, 587–590. [Google Scholar] [CrossRef]
  184. Shin, J.Y.; Lee, Y.B.; Cho, B.K.; Park, H.J. New World Cutaneous Leishmaniasis Treated with Intralesional Injection of Pentavalent Antimony. Ann. Dermatol. 2013, 25, 80–83. [Google Scholar] [CrossRef] [PubMed]
  185. Kuna, A.; Gajewski, M.; Bykowska, M.; Pietkiewicz, H.; Olszański, R.; Myjak, P. Imported Cutaneous Leishmaniasis: A 13-Year Experience of a Polish Tertiary Center. Postepy Derm. Alergol. 2019, 36, 104–111. [Google Scholar] [CrossRef] [PubMed]
  186. Tsai, P.H.; Chen, Y.T.; Liau, J.Y.; Huang, M.H.; Hsu, H.M.; Yeong, E.K.; Hung, C.C. Molecular Diagnosis and Therapy for Cutaneous Leishmaniasis of a Returned Traveler from Mexico. J. Microbiol. Immunol. Infect 2021, 54, 1154–1158. [Google Scholar] [CrossRef] [PubMed]
  187. Kitano, H.; Sanjoba, C.; Goto, Y.; Iwamoto, K.; Kitagawa, H.; Nomura, T.; Omori, K.; Shigemoto, N.; Hide, M.; Matsumoto, Y.; et al. Complicated Cutaneous Leishmaniasis Caused by an Imported Case of Leishmania tropica in Japan: A Case Report. Trop. Med. Health 2021, 49, 20. [Google Scholar] [CrossRef]
  188. Bizri, N.A.; Alam, W.; Khoury, M.; Musharrafieh, U.; Ghosn, N.; Berri, A.; Bizri, A.R. The Association Between the Syrian Crisis and Cutaneous Leishmaniasis in Lebanon. Acta Parasitol. 2021, 66, 1240–1245. [Google Scholar] [CrossRef]
  189. Eldin, C.; L’Ollivier, C.; Ranque, S.; Gautret, P.; Parola, P. “Chiclero’s Ulcer” Due to Leishmania mexicana in Travelers Returning from Central America: A Case Report and Review of the Literature. Pathogens 2021, 10, 1112. [Google Scholar] [CrossRef]
  190. Chong, G.L.M.; Ong, D.S.; de Mendonça Melo, M.; van Hellemond, J.J. Painful and Swollen Tongue: Mucosal Leishmaniasis Due to Leishmania infantum. Int. J. Infect. Dis. 2021, 113, 109–112. [Google Scholar] [CrossRef]
  191. Iannone, M.; Oranges, T.; Dini, V.; Romanelli, M.; Janowska, A. Wound Management Strategy for Treatment of Localized Cutaneous Leishmaniasis Using the TIME Framework. Wounds 2021, 33, E6–E9. [Google Scholar]
  192. Guery, R.; Henry, B.; Martin-Blondel, G.; Rouzaud, C.; Cordoliani, F.; Harms, G.; Gangneux, J.P.; Foulet, F.; Bourrat, E.; Baccard, M.; et al. Liposomal Amphotericin B in Travelers with Cutaneous and Muco-Cutaneous Leishmaniasis: Not a Panacea. PLoS Negl. Trop. Dis. 2017, 11, e0006094. [Google Scholar] [CrossRef]
  193. Lescure, F.; Bonnard, P.; Chandenier, J.; Schmit, J.; Douadi, Y. Atypical Cutaneous Leishmaniasis. Presse. Med. 2002, 31, 259–261. [Google Scholar]
  194. Spinicci, M.; Zammarchi, L.; Gramiccia, M.; di Muccio, T.; Bartolozzi, D.; Corsi, P.; Trotta, M.; Bartoloni, A. Effective Meglumine Antimoniate Intralesional Therapy for Chiclero’s Ulcer Refractory to Systemic Liposomal Amphotericin B. J. Travel Med. 2021, 28, 1–2. [Google Scholar] [CrossRef]
  195. Çizmeci, Z.; Karakuş, M.; Karabela, Ş.N.; Erdoğan, B.; Güleç, N. Leishmaniasis in Istanbul; A New Epidemiological Data about Refugee Leishmaniasis. Acta Trop. 2019, 195, 23–27. [Google Scholar] [CrossRef]
  196. Crowe, A.; Slavin, J.; Stark, D.; Aboltins, C. A Case of Imported Leishmania infantum Cutaneous Leishmaniasis; an Unusual Presentation Occurring 19 Years after Travel. BMC Infect. Dis. 2014, 14, 597. [Google Scholar] [CrossRef]
  197. Darling, M.; Reichenberg, J.; Gavino, A. New World Cutaneous Leishmaniasis: Obstacles in Initiating Treatment with Sodium Stibogluconate in 2 Travelers from Texas-PubMed. J. Drugs Dermatol. 2013, 12, 476–478. [Google Scholar]
  198. Harms, G.; Zenk, J.; Martin, S.; Kokozidou, M.; Püschel, W.; Bienzle, U.; Seitz, H.M. Localized Lymphadenopathy Due to Leishmanial Infection. Infection 2001, 29, 355–356. [Google Scholar] [CrossRef]
  199. Martín-Sánchez, J.; Navarro-Mari, J.M.; Pasquau-Liaǹo, J.; Salomón, O.D.; Morillas-Márquez, F. Visceral Leishmaniasis Caused by Leishmania infantum in a Spanish Patient in Argentina: What Is the Origin of the Infection? Case Report. BMC Infect. Dis. 2004, 4, 20. [Google Scholar] [CrossRef]
  200. Meijer, M.-J.; Kuiper-Kramer, E.; Overbosch, D.; Groeneveld, P.H.P. Fever from the USA or Portugal? Neth. J. Med. 2005, 63, 367. [Google Scholar]
  201. El-Ramli, R.; Koulaouzidis, A. An Unusual Cause for Anaemia. J. Gastrointestin Liver Dis. 2008, 17, 353. [Google Scholar]
  202. Khanlari, B.; Bodmer, M.; Terracciano, L.; Heim, M.H.; Fluckiger, U.; Weisser, M. Hepatitis with Fibrin-Ring Granulomas. Infection 2008, 36, 381–383. [Google Scholar] [CrossRef]
  203. Seilmaier, M.; Hecht, A.; Guggemos, W.; Adorf, D.; Gehbauer, G. Pancytopenia, Hepatosplenomegaly and Dry Cough after Breast Cancer. Dtsch. Med. Wochenschr. 2009, 134, 1269–1273. [Google Scholar] [CrossRef]
  204. Hicks, L.; Kant, P.; Tay, P.H.; Vincini, V.; Schuster, H.; Rotimi, O.; Maughan, N.; Jordan, C.; Moss, S.; Everett, S.; et al. Visceral Leishmaniasis Presenting with Intestinal Failure: A Case Report and Literature Review. Eur. J. Gastroenterol. Hepatol. 2009, 21, 117–122. [Google Scholar] [CrossRef]
  205. Peeters, E.; Verhulst, S.; Wojciechowski, M.; Vlieghe, E.; Jorens, P.; van Marck, V.; Ramet, J.; de Dooy, J. Visceral Leishmaniasis in a Child Infected with the Human Immunodeficiency Virus in a Non-Endemic Region. J. Trop. Pediatr. 2011, 57, 493–495. [Google Scholar] [CrossRef]
  206. Skram, M.K.; Bjering, S.; Hermansen, N.O.; Dini, L.; Hellebostad, M. A 15-Month-Old Girl with Fever and Pancytopenia. Tidsskr. Nor. Laegeforen. 2011, 131, 2482–2486. [Google Scholar] [CrossRef]
  207. Mccusker, L.; Platt, J. An Unusual Case of Anaemia in an Octogenarian. Age Ageing 2012, 41, 696–698. [Google Scholar] [CrossRef]
  208. Cuperis, F.; Oosterwijk, P.; Vos, A.; Ramijn, J.; van Dobbenburgh, A.; Bisseling, T. Visceral Leishmaniasis: Not Only a Tropical Disease. Ned. Tijdschr. Geneeskd. 2013, 157, A5958. [Google Scholar]
  209. Besada, E.; Njålla, R.J.; Nossent, J.C. Imported Case of Visceral Leishmaniasis Presenting as Pancytopenia in a Norwegian Patient Treated with Methotrexate and Etanercept for Psoriasis Arthritis. Rheumatol. Int. 2013, 33, 2687–2689. [Google Scholar] [CrossRef]
  210. Trück, J.; Rampton, C.; Kelly, S.J.; Kelly, D. Visceral Leishmaniasis in an Infant Following a Holiday Trip to Spain. BMJ Case Rep. 2015, 2015. [Google Scholar] [CrossRef]
  211. Alcheikh, A.; Lynar, S.; Brown, C.; Lee, A.; Bryant, C. Unusual Case of Splenomegaly and Pancytopenia in a Returned Traveller. Intern. Med. J. 2017, 47, 1325–1326. [Google Scholar] [CrossRef]
  212. Adamczick, C.; Dierig, A.; Welzel, T.; Schifferli, A.; Blum, J.; Ritz, N. Double Trouble: Visceral Leishmaniasis in Twins after Traveling to Tuscany—A Case Report. BMC Infect. Dis. 2018, 18, 495. [Google Scholar] [CrossRef]
  213. Depaquit, J.; Kaltenbach, M.L.; Gay, F. Visceral Leishmaniasis in Traveler to Guyana Caused by Leishmania Siamensis, London, UK. Emerg. Infect. Dis. 2018, 24, 1599–1600. [Google Scholar] [CrossRef]
  214. Theodosiou, A.; Hiew, H.; Petridou, C. An Acute Presentation of Haemophagocytic Lymphohistiocytosis Due to Visceral Leishmaniasis in a British Adult Returning Traveller. Acute Med. 2019, 18, 184–188. [Google Scholar] [CrossRef] [PubMed]
  215. Ahmed, A.A.; Li, W.; Livingston, R.A. Travelling with Visceral Leishmaniasis. Clin. Microbiol. Infect. 2020, 26, 454–455. [Google Scholar] [CrossRef] [PubMed]
  216. Vécsei, A.; Kastner, U.; Trebo, M.; Kornmüller, R.; Picher, O.; Schratzberger-Vécsei, E.; Gadner, H. Pediatric Visceral Leishmaniasis in Austria: Diagnostic Difficulties in a Non-Endemic Region. Wien. Klin. Wochenschr. 2001, 113, 102–106. [Google Scholar] [PubMed]
  217. Kaae, J.; Nørgaard, P.; Himmelstrup, B. Visceral Leishmaniasis Diagnosed in a Patient with MALT Lymphoma. Eur. J. Intern. Med. 2007, 18, 235–237. [Google Scholar] [CrossRef]
  218. Suvajdžić, N.; Pavlović, M.; Mišić, S.; Čemerikić, V.; Atkinson, H.D.A.; Čolović, M. Secondary Myelofibrosis in Visceral Leishmaniasis—Case Report. Haematologia 2001, 31, 167–171. [Google Scholar] [CrossRef]
  219. Minakaran, N.; Soorma, T.; Ladhani, S.N. Visceral Leishmaniasis in a UK Toddler Following a Short Trip to a Popular Holiday Destination in Spain. Case Rep. Infect. Dis. 2014, 2014, 1–3. [Google Scholar] [CrossRef]
  220. Rayatt, S.S.; Moss, A.L.H. Cutaneous Leishmaniasis. Br. J. Plast. Surg. 2000, 53, 443–445. [Google Scholar] [CrossRef]
  221. ME, W.; LC, L. Photo Quiz. Healthy Student with a Papule. New World Cutaneous Leishmaniasis. Clin. Infect. Dis. 2001, 33, 816. [Google Scholar] [CrossRef]
  222. Loo, W.J.; Lishman, S.C.; Lockwood, D.N.J.; Todd, P.M. Case 2. Cutaneous Leishmaniasis, Leishmania Amastigotes. Clin. Exp. Dermatol. 2003, 28, 567–568. [Google Scholar] [CrossRef]
  223. Clayton, R.; Grabczynska, S. Mucocutaneous Leishmaniasi.is Presenting as Facial Cellulitis. J. Laryngol. Otol. 2005, 119, 567–569. [Google Scholar] [CrossRef]
  224. Mirzabeigi, M.; Farooq, U.; Baraniak, S.; Dowdy, L.; Ciancio, G.; Vincek, V. Reactivation of Dormant Cutaneous Leishmania Infection in a Kidney Transplant Patient. J. Cutan. Pathol. 2006, 33, 701–704. [Google Scholar] [CrossRef]
  225. Darné, S.; Sinclair, S.A. A Sandfly in Surrey? A Case of Cutaneous Leishmaniasis in the United Kingdom without History of Recent Travel to an Endemic Area. Clin. Exp. Dermatol. 2006, 31, 155–156. [Google Scholar] [CrossRef]
  226. Flaig, M.J.; Rupec, J.; Ruzicka, T.; Rupec, R.A. Topical Treatment of Persistent Cutaneous Leishmaniasis with Paromomycin. Hautarzt 2007, 58, 689–692. [Google Scholar] [CrossRef]
  227. Herrmann, A.; Wohlrab, J.; Sudeck, H.; Burchard, G.D.; Marsch, W.C. Chronic Lupoid Leishmaniasis. A Rare Differential Diagnosis in Germany for Erythematous Infiltrative Facial Plaques. Hautarzt 2007, 58, 256–260. [Google Scholar] [CrossRef]
  228. Mings, S.; Beck, J.C.; Davidson, C.; Ondo, A.L.; Shanler, S.D.; Berman, J. Cutaneous Leishmaniasis with Boggy Induration and Simultaneous Mucosal Disease. Am. J. Trop. Med. Hyg. 2009, 80, 3–5. [Google Scholar] [CrossRef]
  229. Faber, W.R.; Wonders, J.; Jensema, A.J.; Chocholova, E.; Kager, P.A. Cutaneous Leishmaniasis with Lymphadenopathy Due to Leishmania donovani. Clin. Exp. Dermatol. 2009, 34, e196–e198. [Google Scholar] [CrossRef]
  230. Stewardson, A.J.; Leder, K.; Torresi, J.; Johnson, D.F. Two Cases of Old World Cutaneous Leishmaniasis in Australian Travelers Visiting Morocco. J. Travel Med. 2010, 17, 278–280. [Google Scholar] [CrossRef]
  231. Merino, P.; González, F.; Herreros, B.; Picazo, J. Traveler with Multiple Skin Lesions of Six Months’ Evolution. Enferm. Infecc. Y Microbiol. Clin. 2010, 28, 323–324. [Google Scholar] [CrossRef]
  232. Poeppl, W.; Walochnik, J.; Pustelnik, T.; Auer, H.; Mooseder, G. Cutaneous Leishmaniasis after Travel to Cyprus and Successful Treatment with Miltefosine. Am. J. Trop. Med. Hyg. 2011, 84, 562–565. [Google Scholar] [CrossRef]
  233. Neumayr, A.L.C.; Walter, C.; Stoeckle, M.; Braendle, N.; Glatz, K.; Blum, J.A. Successful Treatment of Imported Mucosal Leishmania infantum Leishmaniasis with Miltefosine after Severe Hypokalemia under Meglumine Antimoniate Treatment. J. Travel Med. 2012, 19, 124–126. [Google Scholar] [CrossRef]
  234. Schwartz, R.A.; Kapila, R.; McElligott, S.C.; Atkin, S.H.; Lambert, W.C. Cutaneous Leishmaniasis and Rickettsial African Tick-Bite Fever: A Combination of Exotic Traveler’s Diseases in the Same Patient. Int. J. Dermatol. 2012, 51, 960–963. [Google Scholar] [CrossRef]
  235. Newlove, T.; Robinson, M.; Meehan, S.A.; Pomerantz, R. Old World Cutaneous Leishmaniasis. Derm. Online J. 2012, 18, 32. [Google Scholar] [CrossRef]
  236. Ondriska, F.; Bukovinova, P.; Votypka, J.; Nohynkova, E.; Boldis, V. Imported New World Cutaneous Leishmaniasis in a Traveller from Slovakia. Bratisl. Lek. Listy. 2015, 116, 203–206. [Google Scholar] [CrossRef]
  237. Montalvo, A.M.; de Armas, Y.; Fraga, J.; Blanco, O.; Menéndez, R.; Montoto, V.; Capó de Paz, V. Molecular and Histological Tools to Diagnose an Imported Case of American Cutaneous Leishmaniasis in Cuba. Int. J. Dermatol. 2015, 54, 1175–1179. [Google Scholar] [CrossRef]
  238. Basnett, A.; Nguyen, T.A.; Cannavino, C.; Krakowski, A.C. Ablative Fractional Laser Resurfacing with Topical Paromomycin as Adjunctive Treatment for a Recalcitrant Cutaneous Leishmaniasis Wound. Lasers. Surg. Med. 2015, 47, 788–791. [Google Scholar] [CrossRef]
  239. Mongkolrattanothai, K.; Nadipuram, S.M.; Krakowski, A.C.; Stone, M.M.; Krogstad, P.; Lehman, D. Leishmaniasis Gone Viral: Social Media and an Outbreak of Cutaneous Leishmaniasis. Pediatr. Dermatol. 2016, 33, e276–e277. [Google Scholar] [CrossRef]
  240. Kuilder, J.S.; Wismans, P.J.; Baerveldt, E.M.; van Hellemond, J.J.; de Mendonça Melo, M.; van Genderen, P.J.J. Leishmania Major Cutaneous Leishmaniasis in 3 Travelers Returning from Israel to the Netherlands. Emerg. Infect. Dis. 2016, 22, 2022–2024. [Google Scholar] [CrossRef]
  241. Colson, F.; Boufflette, N.; Somja, J.; Hayette, M.; Nikkels, A. Image of the Month: Travel Souvenir. Rev. Med. Liege 2017, 72, 429–431. [Google Scholar]
  242. Schüürmann, M.; Kunz, M.; Lübbert, C. Oriental Sore (Old-World Cutaneous Leishmaniasis). Dtsch. Arztebl. Int. 2017, 114, 754. [Google Scholar] [CrossRef]
  243. Ganjaei, K.G.; Lawton, K.; Gaur, S. Cutaneous Leishmaniasis in an American Adolescent Returning From Israel. J. Pediatric. Infect. Dis. Soc. 2018, 7, E178–E181. [Google Scholar] [CrossRef]
  244. Watson, I.T.; Patel, R.C.; Jahan-Tigh, R.R. Extensive, Multifocal Cutaneous Leishmaniasis Presenting with Varied Morphologies in an Immunosuppressed Patient. Am. J. Trop. Med. Hyg. 2019, 101, 281–282. [Google Scholar] [CrossRef] [PubMed]
  245. Suqati, A.A.; Pudszuhn, A.; Hofmann, V.M. Mucocutaneous Leishmaniasis: Case Report and Literature Review of a Rare Endonasal Infection. Pan. Afr. Med. J. 2020, 36, 292. [Google Scholar] [CrossRef] [PubMed]
  246. van Kesteren, L.; Maniewski, U.; Bottieau, E.; Cnops, L.; Huits, R. Cutaneous Leishmaniasis in Syrian Refugee Children: A Case Series. Pediatr. Infect. Dis. J. 2020, 39, E154–E156. [Google Scholar] [CrossRef] [PubMed]
  247. Gilkey, T.; Ulman, C.A.; McGwire, B.; Plaza, J.A. Cutaneous Leishmania aethiopica Diagnosed in the United States. Dermatol. Online J. 2021, 27. [Google Scholar] [CrossRef]
  248. Update: Cutaneous Leishmaniasis in U.S. Military Personnel—Southwest/Central Asia, 2002–2004. Available online: https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5312a4.htm (accessed on 13 July 2022).
  249. Révész, T.; Wolfs, T.F.; Kardos, G.; Van Furth, A.M. Visceral Leishmaniasis: Also Beware of These Deceptive Microbes in Non-Endemic Countries! Arch. Dis. Child. 2001, 84, 373b–3373. [Google Scholar] [CrossRef]
  250. Epple, H.J.; Harms, G.; Notter, M.; Husack, R.; Zeitz, M.; Schneider, T. HIV Positive Patient with Pancytopenia and Massive Splenomegaly. Internist 2003, 44, 1031–1036. [Google Scholar] [CrossRef]
  251. Ju, O.; Grove, D.I.; Jaksic, W.J.; Dart, G.W. Visceral Leishmaniasis: A Trip to the Greek Islands Is Not Always Idyllic. Med. J. Aust. 2004, 181, 446–447. [Google Scholar] [CrossRef]
  252. Moore, J.; Brown, K. Sun, Sangria and Sandflies: Leishmaniasis in an Immunosuppressed Patient Returning from Spain. Travel Med. Infect. Dis. 2013, 11, 119–122. [Google Scholar] [CrossRef]
  253. Polley, S.D.; Watson, J.; Chiodini, P.L.; Lockwood, D.N.J. Visceral Leishmaniasis in Traveler to Guyana Caused by Leishmania Siamensis, London, UK. Emerg. Infect. Dis. 2018, 24, 155–156. [Google Scholar] [CrossRef]
  254. Ellner, K.; Darie, H.; Goesch, J.; Consigny, P.H. 61-Year-Old Woman with Formation of Nodules after a Tropical Journey. Dtsch. Med. Wochenschr. 2012, 137, 2263–2264. [Google Scholar] [CrossRef]
  255. Nasri, J.; Cajacob, L.; Wirz, E.; Ruf, M.T.; Blum, J.; Mühleisen, B.; Navarini, A.A.; Maul, L.v. Pre-Ulcerative Leishmaniasis Mimicking Chilblains in a Returning Traveller from Southern Europe. J. Eur. Acad. Dermatol. Venereol. 2021, 35, e503–e505. [Google Scholar] [CrossRef]
  256. Stefaniak, J.; Malgorzata, P.; Kacprzak, E.; Skoryna-Karcz, B. Visceral Leishmaniasis. Przegl. Epidemiol. 2003, 57, 341–348. [Google Scholar]
  257. Malik, A.N.J.; John, L.; Bryceson, A.D.M.; Lockwood, D.N.J. Changing Pattern of Visceral Leishmaniasis, United Kingdom, 1985–2004. Emerg. Infect. Dis. 2006, 12, 1257–1259. [Google Scholar] [CrossRef]
  258. Aardema, H.; Sijpkens, Y.W.J.; Visser, L.G. Pancytopenia in a Simultaneous Pancreas and Kidney Transplant Recipient: An Unexpected Cause—A Case of Visceral Leishmaniasis in a Transplant Recipient. Clin. Nephrol. 2009, 71, 460–462. [Google Scholar] [CrossRef]
  259. El-Moamly, A.; El-Sweify, M.; Hafeez, M. Performance of RK39 Immunochromatography and Freeze-Dried Direct Agglutination Tests in the Diagnosis of Imported Visceral Leishmaniasis. Parasitol. Res. 2012, 110, 349–354. [Google Scholar] [CrossRef]
  260. Ehehalt, U.; Schunk, M.; Jensenius, M.; van Genderen, P.J.J.; Gkrania-Klotsas, E.; Chappuis, F.; Schlagenhauf, P.; Castelli, F.; Lopez-Velez, R.; Parola, P.; et al. Leishmaniasis Acquired by Travellers to Endemic Regions in Europe: A EuroTravNet Multi-Centre Study. Travel Med. Infect. Dis. 2014, 12, 167–172. [Google Scholar] [CrossRef]
  261. Fletcher, K.; Issa, R.; Lockwood, D.N.J. Visceral Leishmaniasis and Immunocompromise as a Risk Factor for the Development of Visceral Leishmaniasis: A Changing Pattern at the Hospital for Tropical Diseases, London. PLoS ONE 2015, 10, e0121418. [Google Scholar] [CrossRef]
  262. Dakić, Z.; Nikolić, A.; Lavadinović, L.; Pelemiš, M.; Klun, I.; Dulović, O.; Milošević, B.; Stevanović, G.; Ofori-Belić, I.; Poluga, J.; et al. Imported Parasitic Infections in Serbia. Eur. J. Microbiol. Immunol. 2011, 1, 80–85. [Google Scholar] [CrossRef]
  263. Lange, C.G.; Salata, R.A. Cutaneous Leishmaniasis. Med. Klin. 2001, 96, 561–562. [Google Scholar] [CrossRef]
  264. Schönian, G.; Nasereddin, A.; Dinse, N.; Schweynoch, C.; Schallig, H.D.F.H.; Presber, W.; Jaffe, C.L. PCR Diagnosis and Characterization of Leishmania in Local and Imported Clinical Samples. Diagn. Microbiol. Infect. Dis. 2003, 47, 349–358. [Google Scholar] [CrossRef]
  265. Stienlauf, S.; Segal, G.; Sidi, Y.; Schwartz, E. Epidemiology of Travel-Related Hospitalization. J. Travel Med. 2005, 12, 136–141. [Google Scholar] [CrossRef]
  266. Royer, M.; Crowe, M. American Cutaneous Leishmaniasis: A Cluster of 3 Cases during Military Training in Panama. Arch. Pathol. Lab. Med. 2002, 126, 471. [Google Scholar] [CrossRef]
  267. Bailey, M.S. Cutaneous Leishmaniasis in British Troops Following Jungle Training in Belize. Travel Med. Infect. Dis. 2011, 9, 253–254. [Google Scholar] [CrossRef]
  268. Yang, Y.-T.; Zhang, M.; Gao, C.-H.; Shi, F.; Guan, L.-R.; Wang, J.-Y. Detection and Species Identification of Two Imported Cases of Cutaneous Leishmaniasis. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi 2011, 29, 461–464. [Google Scholar]
  269. van Thiel, P.P.A.M.; Zeegelaar, J.E.; van Gool, T.; Faber, W.R.; Kager, P.A. Cutaneous Leishmaniasis in Three Dutch Military Cohorts Following Jungle Training in Belize. Travel Med. Infect. Dis. 2011, 9, 153–160. [Google Scholar] [CrossRef]
  270. Boggild, A.K.; Geduld, J.; Libman, M.; Ward, B.J.; McCarthy, A.; Hajek, J.; Ghesquiere, W.; Vincelette, J.; Kuhn, S.; Freedman, D.; et al. Travel-Acquired Infections in Canada: CanTravNet 2011–2012. Can. Commun. Dis. Rep. 2014, 40, 313–325. [Google Scholar] [CrossRef]
  271. Zhao, Y.L.; Li, S.H.; Zhu, X.; Zhou, R.M.; Yang, C.Y.; Liu, Y.; Niu, Y.N.; Lu, D.L.; Zhang, H.W.; Zhao, D.Y. Investigating the Aggregation of Imported Cutaneous Leishmaniasis in Henan, Central China. Biomed. Environ. Sci. 2021, 34, 247–249. [Google Scholar] [CrossRef]
  272. Field, V.; Gautret, P.; Schlagenhauf, P.; Burchard, G.D.; Caumes, E.; Jensenius, M.; Castelli, F.; Gkrania-Klotsas, E.; Weld, L.; Lopez-Velez, R.; et al. Travel and Migration Associated Infectious Diseases Morbidity in Europe, 2008. BMC Infect. Dis. 2010, 10, 330. [Google Scholar] [CrossRef] [PubMed]
  273. Silgado, A.; Armas, M.; Sánchez-Montalvá, A.; Goterris, L.; Ubals, M.; Temprana-Salvador, J.; Aparicio, G.; Chicharro, C.; Serre-Delcor, N.; Ferrer, B.; et al. Changes in the Microbiological Diagnosis and Epidemiology of Cutaneous Leishmaniasis in Real-Time PCR Era: A Six-Year Experience in a Referral Center in Barcelona. PLoS Negl. Trop. Dis. 2021, 15, e0009884. [Google Scholar] [CrossRef] [PubMed]
  274. Saroufim, M.; Charafeddine, K.; Issa, G.; Khalifeh, H.; Habib, R.H.; Berry, A.; Ghosn, N.; Rady, A.; Khalifeh, I. Ongoing Epidemic of Cutaneous Leishmaniasis among Syrian Refugees, Lebanon. Emerg. Infect. Dis. 2014, 20, 1712–1715. [Google Scholar] [CrossRef] [PubMed]
  275. Özbilgin, A.; Gencoglan, G.; Tunali, V.; Çavuş, İ.; Yıldırım, A.; Gündüz, C.; Harman, M. Refugees at the Crossroads of Continents: A Molecular Approach for Cutaneous Leishmaniasis Among Refugees in Turkey. Acta Parasitol. 2020, 65, 136–143. [Google Scholar] [CrossRef]
  276. Monteiro, W.M.; Neitzke-Abreu, H.C.; Ferreira, M.E.M.D.C.; de Melo, G.C.; Barbosa, M.D.G.V.; Lonardoni, M.V.C.; Silveira, T.G.V.; Teodoro, U. Population Mobility and Production of American Tegumentary Leishmaniasis in the State of Paraná, Southern Brazil. Rev. Soc. Bras. Med. Trop. 2009, 42, 509–514. [Google Scholar] [CrossRef]
  277. Morizot, G.; Kendjo, E.; Mouri, O.; Thellier, M.; Pérignon, A.; Foulet, F.; Cordoliani, F.; Bourrat, E.; Laffitte, E.; Alcaraz, I.; et al. Travelers with Cutaneous Leishmaniasis Cured without Systemic Therapy. Clin. Infect. Dis. 2013, 57, 370–380. [Google Scholar] [CrossRef]
  278. Mohammadi, A.; Khamesipour, A.; Khatami, A.; Javadi, A.; Nassiri-Kashani, M.; Firooz, A.; Dowlati, Y.; Behnia, M.; Eskandari, S. Cutaneous Leishmaniasis in Suspected Patients Referred to the Center for Research and Training in Skin Diseases and Leprosy, Tehran, Iran from 2008 to 2011. Iran. J. Parasitol. 2013, 8, 430–436. [Google Scholar]
  279. Centers for Disease Control and Prevention (CDC) Update: Cutaneous Leishmaniasis in U.S. Military Personnel—Southwest/Central Asia, 2002–2004. MMWR Morb. Mortal. Wkly. Rep. 2004, 264–265.
  280. Rawlins, T.T.S.C. American Cutaneous Leishmaniasis in Guyana, South America. Ann. Trop. Med. Parasitol. 2001, 95, 245–251. [Google Scholar] [CrossRef]
  281. Alcântara de Castro, E.A.; Thomaz Soccol, V.; Membrive, N.; Luz, E. Epidemiological and Clinical Study of 332 Cases of Cutaneous Leishmaniasis in the North of Parana State from 1993 to 1998. Rev. Soc. Bras. Med. Trop. 2002, 35, 445–452. [Google Scholar] [CrossRef]
  282. Ahluwalia, S.; Lawn, S.D.; Kanagalingam, J.; Grant, H.; Lockwood, D.N.J. Mucocutaneous Leishmaniasis: An Imported Infection among Travellers to Central and South America. BMJ 2004, 329, 842–844. [Google Scholar] [CrossRef]
  283. Gradoni, L. Epidemiological Surveillance of Leishmaniasis in the European Union: Operational and Research Challenges. Euro Surveill. 2013, 18, 20539. [Google Scholar] [CrossRef]
  284. Blum, J. LeishMan: Harmonising Diagnostic and Clinical Management of Leishmaniasis in Europe. Euro Surveill. 2013, 18, 20538. [Google Scholar] [CrossRef]
  285. Zijlstra, E.E.; El-Hassan, A.M. Leishmaniasis in Sudan. Visceral Leishmaniasis. Trans. R Soc. Trop. Med. Hyg. 2001, 95 (Suppl. S1), S27–S58. [Google Scholar] [CrossRef]
  286. Pagliano, P.; Rossi, M.; Rescigno, C.; Altieri, S.; Coppola, M.G.; Gramiccia, M.; Scalone, A.; Gradoni, L.; Faella, F. Mediterranean Visceral Leishmaniasis in HIV-Negative Adults: A Retrospective Analysis of 64 Consecutive Cases (1995–2001). J. Antimicrob. Chemother. 2003, 52, 264–268. [Google Scholar] [CrossRef]
  287. Gupta, N.; Kant, K.; Mirdha, B. Clinical and Laboratory Analysis of Patients with Leishmaniasis: A Retrospective Study from a Tertiary Care Center in New Delhi. Iran. J. Parasitol. 2017, 12, 632–637. [Google Scholar]
  288. Brum, N.F.F.; Coelho, J.S.; Carvalho, L.S.; Vieira, M.N.O.; Bentes, A.A.; Carellos, E.V.M.; Diniz, L.M.O.; Carvalho, A.L.; Romanelli, R.M.d.C. Hemophagocytic Lymphohistiocytosis and Visceral Leishmaniasis in Children: A Series of Cases and Literature Review. Rev. Paul. Pediatr. 2021, 40, e2020269. [Google Scholar] [CrossRef]
  289. Manomat, J.; Leelayoova, S.; Bualert, L.; Tan-ariya, P.; Siripattanapipong, S.; Mungthin, M.; Naaglor, T.; Piyaraj, P. Prevalence and Risk Factors Associated with Leishmania Infection in Trang Province, Southern Thailand. PLoS Negl. Trop. Dis. 2017, 11, e0006095. [Google Scholar] [CrossRef]
  290. Karamian, M.; Motazedian, M.H.; Mehrabani, D.; Gholami, K. Leishmania major Infection in a Patient with Visceral Leishmaniasis: Treatment with Amphotericin B. Parasitol. Res. 2007, 101, 1431–1434. [Google Scholar] [CrossRef]
  291. Ravel, C.; Cortes, S.; Pratlong, F.; Morio, F.; Dedet, J.-P.; Campino, L. First Report of Genetic Hybrids between Two Very Divergent Leishmania Species: Leishmania infantum and Leishmania major. Int. J. Parasitol. 2006, 36, 1383–1388. [Google Scholar] [CrossRef]
  292. Babiker, A.M.; Ravagnan, S.; Fusaro, A.; Hassan, M.M.; Bakheit, S.M.; Mukhtar, M.M.; Cattoli, G.; Capelli, G. Concomitant Infection with Leishmania donovani and L. major in Single Ulcers of Cutaneous Leishmaniasis Patients from Sudan. J. Trop. Med. 2014, 2014. [Google Scholar] [CrossRef] [PubMed]
  293. Badirzadeh, A.; Mohebali, M.; Sabzevari, S.; Ghafoori, M.; Arzamani, K.; Seyyedin, M.; Hashemi, S.A. Case Report: First Coinfection Report of Mixed Leishmania infantum/Leishmania major and Human Immunodeficiency Virus-Acquired Immune Deficiency Syndrome: Report of a Case of Disseminated Cutaneous Leishmaniasis in Iran. Am. J. Trop. Med. Hyg. 2018, 98, 122–125. [Google Scholar] [CrossRef]
  294. al Balushi, A.; Khamis, F.; Klaassen, C.H.W.; Gangneux, J.P.; van Hellemond, J.J.; Petersen, E. Double Infection With Leishmania tropica and L. major in an HIV Patient Controlled With High Doses of Amphotericin B. Open Forum Infect. Dis. 2018, 5. [Google Scholar] [CrossRef]
  295. Antinori, S.; Cascio, A.; Parravicini, C.; Bianchi, R.; Corbellino, M. Leishmaniasis among Organ Transplant Recipients. Lancet Infect. Dis 2008, 8, 191–199. [Google Scholar] [CrossRef]
  296. Diro, E.; Lynen, L.; Ritmeijer, K.; Boelaert, M.; Hailu, A.; van Griensven, J. Visceral Leishmaniasis and HIV Coinfection in East Africa. PLoS Negl. Trop. Dis. 2014, 8. [Google Scholar] [CrossRef] [PubMed]
  297. WHO Guideline for the Treatment of Visceral Leishmaniasis in HIV Co-Infected Patients in East Africa and South-East Asia [Internet]-PubMed. Available online: https://pubmed.ncbi.nlm.nih.gov/35763584/ (accessed on 19 July 2022).
  298. UNHCR-Global Trends in Forced Displacement-2020. Available online: https://www.unhcr.org/60b638e37/unhcr-global-trends-2020 (accessed on 3 March 2022).
  299. Saab, M.; el Hage, H.; Charafeddine, K.; Habib, R.H.; Khalifeh, I. Diagnosis of Cutaneous Leishmaniasis: Why Punch When You Can Scrape? Am. J. Trop. Med. Hyg. 2015, 92, 518. [Google Scholar] [CrossRef] [PubMed]
  300. Zanetti, A.D.S.; Sato, C.M.; Longhi, F.G.; Ferreira, S.M.B.; Espinosa, O.A. Diagnostic Accuracy of Enzyme-Linked Immunosorbent Assays to Detect Anti-Leishmania Antibodies in Patients with American Tegumentary Leishmaniasis: A Systematic Review. Rev. Inst. Med. Trop. S. Paulo 2019, 61, e42. [Google Scholar] [CrossRef]
  301. Maroli, M.; Feliciangeli, M.D.; Bichaud, L.; Charrel, R.N.; Gradoni, L. Phlebotomine Sandflies and the Spreading of Leishmaniases and Other Diseases of Public Health Concern. Med. Vet. Entomol. 2013, 27, 123–147. [Google Scholar] [CrossRef]
  302. Du, R.; Hotez, P.J.; Al-Salem, W.S.; Acosta-Serrano, A. Old World Cutaneous Leishmaniasis and Refugee Crises in the Middle East and North Africa. PLoS Negl. Trop. Dis. 2016, 10, e0004545. [Google Scholar] [CrossRef]
  303. van der Werf, J.; Derrough, T.; Duffell, E.; Pharris, A.; Suk, J.; De, H.; Gomes, C.; Mårdh, O.; Velasco Muñoz, C.; Causevic, S.; et al. Public Health Guidance on Screening and Vaccination for Infectious Diseases in Newly Arrived Migrants within the EU/EEA; European Centre for Disease Prevention and Control: Solna, Sweden, 2018. [Google Scholar] [CrossRef]
  304. Badenes, M.; Aguilar, A.; Massagué, C.; Carrasco, C.; de Gispert, B.; Fernández, J.; Roca, C.; Roura, S.; Sànchez, R.; Solsona, L.; et al. Guiad’atenció Primària al Pacient Immigrant Segona Edició. 2011. Available online: http://gestor.camfic.cat/Uploads/ITEM_413_EBLOG_1916.pdf. (accessed on 19 July 2022).
  305. Vergel, C.; Palacios, R.; Cadena, H.; Posso, C.J.; Valderrama, L.; Perez, M.; Walker, J.; Travi, B.L.; Saravia, N.G. Evidence for Leishmania (Viannia) Parasites in the Skin and Blood of Patients Before and After Treatment. J. Infect. Dis. 2006, 194, 503–511. [Google Scholar] [CrossRef]
  306. European Centre for Disease Prevention and Control (ECDC). Phlebotomus sergenti-Current Known Distribution: March 2022. Available online: https://www.ecdc.europa.eu/en/publications-data/phlebotomus-sergenti-current-known-distribution-march-2022 (accessed on 19 July 2022).
  307. European Centre for Disease Prevention and Control (ECDC). Phlebotomus perniciosus-Current Known Distribution: January 2019. Available online: https://www.ecdc.europa.eu/en/publications-data/phlebotomus-perniciosus-current-known-distribution-january-2019 (accessed on 3 March 2022).
  308. Bongiorno, G.; di Muccio, T.; Bianchi, R.; Gramiccia, M.; Gradoni, L. Laboratory Transmission of an Asian Strain of Leishmania tropica by the Bite of the Southern European Sand Fly Phlebotomus Perniciosus. Int. J. Parasitol. 2019, 49, 417–421. [Google Scholar] [CrossRef]
  309. Vaselek, S.; Volf, P. Experimental Infection of Phlebotomus perniciosus and Phlebotomus tobbi with Different Leishmania tropica Strains. Int. J. Parasitol. 2019, 49, 831–835. [Google Scholar] [CrossRef]
  310. Antoniou, M.; Gramiccia, M.; Molina, R.; Dvorak, V.; Volf, P. The Role of Indigenous Phlebotomine Sandflies and Mammals in the Spreading of Leishmaniasis Agents in the Mediterranean Region. Euro. Surveill. 2013, 18, 20540. [Google Scholar] [CrossRef]
  311. Fotakis, E.A.; Giantsis, I.A.; Avgerinou, A.; Kourtidis, S.; Agathaggelidou, E.; Kapoula, C.; Dadakou, G.; Vontas, J.; Chaskopoulou, A. Identification of Leishmania Species in Naturally Infected Sand Flies from Refugee Camps, Greece. Emerg. Infect. Dis. 2019, 25, 361–364. [Google Scholar] [CrossRef]
  312. Campino, L.; Maia, C. The Role of Reservoirs: Canine Leishmaniasis. In Drug Resistance in Leishmania Parasites–Consequences, Molecular Mechanism and Possible Treatments; Ponte-Sucre, A., Padron-Nieves, M., Diaz, E., Eds.; Springer: Berlin/Heidelberg, Germany, 2018; pp. 59–83. [Google Scholar]
  313. Faiman, R.; Abbasi, I.; Jaffe, C.; Motro, Y.; Nasereddin, A.; Schnur, L.F.; Torem, M.; Pratlong, F.; Dedet, J.P.; Warburg, A. A Newly Emerged Cutaneous Leishmaniasis Focus in Northern Israel and Two New Reservoir Hosts of Leishmania major. PLoS Negl. Trop. Dis. 2013, 7, e2058. [Google Scholar] [CrossRef]
  314. Svárovská, A.; Ant, T.H.; Seblová, V.; Jecná, L.; Beverley, S.M.; Volf, P. Leishmania major Glycosylation Mutants Require Phosphoglycans (Lpg2-) but Not Lipophosphoglycan (Lpg1-) for Survival in Permissive Sand Fly Vectors. PLoS Negl. Trop. Dis. 2010, 4, e580. [Google Scholar] [CrossRef]
  315. Seblova, V.; Myskova, J.; Hlavacova, J.; Votypka, J.; Antoniou, M.; Volf, P. Natural Hybrid of Leishmania infantum/L. donovani: Development in Phlebotomus tobbi, P. perniciosus and Lutzomyia longipalpis and Comparison with Non-Hybrid Strains Differing in Tissue Tropism. Parasit Vectors 2015, 8, 605. [Google Scholar] [CrossRef]
  316. Campino, L.; Cortes, S.; Dionísio, L.; Neto, L.; Afonso, M.O.; Maia, C. The First Detection of Leishmania major in Naturally Infected Sergentomyia minuta in Portugal. Mem. Inst. Oswaldo. Cruz. 2013, 108, 516–518. [Google Scholar] [CrossRef]
  317. Pereira, A.; Parreira, R.; Cristóvão, J.M.; Castelli, G.; Bruno, F.; Vitale, F.; Campino, L.; Maia, C. Phylogenetic Insights on Leishmania Detected in Cats as Revealed by Nucleotide Sequence Analysis of Multiple Genetic Markers. Infect. Genet. Evol. 2020, 77, 104069. [Google Scholar] [CrossRef]
  318. Antoniou, M.; Haralambous, C.; Mazeris, A.; Pratlong, F.; Dedet, J.P.; Soteriadou, K. Leishmania donovani Leishmaniasis in Cyprus. Lancet. Infect. Dis. 2008, 8, 6–7. [Google Scholar] [CrossRef]
  319. Rogers, M.B.; Downing, T.; Smith, B.A.; Imamura, H.; Sanders, M.; Svobodova, M.; Volf, P.; Berriman, M.; Cotton, J.A.; Smith, D.F. Genomic confirmation of hybridisation and recent inbreeding in a vector-isolated Leishmania population. PLoS Genet. 2014, 10, e1004092. [Google Scholar] [CrossRef]
  320. WHO. Control of the Leishmaniasis: Report of the Who Expert Committee on the Control of Leishmaniases; WHO Technical Report Series; WHO: Geneva, Switzerland, 2010; ISBN 9789241209496. [Google Scholar]
  321. Kato, H.; Cáceres, A.G.; Gomez, E.A.; Tabbabi, A.; Mizushima, D.; Yamamoto, D.S.; Hashiguchi, Y. Prevalence of Genetically Complex Leishmania Strains With Hybrid and Mito-Nuclear Discordance. Front. Cell Infect. Microbiol. 2021, 11, 625001. [Google Scholar] [CrossRef]
  322. Volf, P.; Benkova, I.; Myskova, J.; Sadlova, J.; Campino, L.; Ravel, C. Increased Transmission Potential of Leishmania major/Leishmania infantum Hybrids. Int. J. Parasitol. 2007, 37, 589–593. [Google Scholar] [CrossRef]
  323. van Griensven, J.; Carrillo, E.; López-Vélez, R.; Lynen, L.; Moreno, J. Leishmaniasis in Immunosuppressed Individuals. Clin. Microbiol. Infect. 2014, 20, 286–299. [Google Scholar] [CrossRef]
  324. Singh, O.P.; Tiwary, P.; Kushwaha, A.K.; Singh, S.K.; Singh, D.K.; Lawyer, P.; Rowton, E.; Chaubey, R.; Singh, A.K.; Rai, T.K.; et al. Xenodiagnosis to Evaluate the Infectiousness of Humans to Sandflies in an Area Endemic for Visceral Leishmaniasis in Bihar, India: A Transmission-Dynamics Study. Lancet Microbe 2021, 2, e23–e31. [Google Scholar] [CrossRef]
  325. Gómez, P.N.; Hidalgo, I.C.; de La Paz Casas Hidalgo, M.; Sánchez, R.Á.; Delgado, A.R.; Cabeza-Barrera, J. Cutaneous Leishmaniasis Associated with TNF-α Blockers: A Case Report. Eur. J. Hosp. Pharm. 2019, 26, 233–234. [Google Scholar] [CrossRef]
  326. Bosch-Nicolau, P.; Ubals, M.; Salvador, F.; Sánchez-Montalvá, A.; Aparicio, G.; Erra, A.; de Salazar, P.M.; Sulleiro, E.; Molina, I. Leishmaniasis and Tumor Necrosis Factor Alpha Antagonists in the Mediterranean Basin. A Switch in Clinical Expression. PLoS Negl. Tro.p Dis. 2019, 13, e0007708. [Google Scholar] [CrossRef]
  327. Surveillance, Prevention and Control of Leishmaniases in the European Union and Its Neighbouring Countries. Available online: https://www.ecdc.europa.eu/en/publications-data/surveillance-prevention-control-leishmaniases-European-Union-and-neighbouring-countries (accessed on 19 July 2022).
Pathogens 11 00921 g001 550
Figure 1. A flow diagram of the study search and selection process.
Figure 1. A flow diagram of the study search and selection process.
Pathogens 11 00921 g001
Pathogens 11 00921 g002 550
Figure 2. The number of cases of visceral leishmaniasis diagnosed, by country of travel or migration.
Figure 2. The number of cases of visceral leishmaniasis diagnosed, by country of travel or migration.
Pathogens 11 00921 g002
Pathogens 11 00921 g004 550
Figure 4. The combined number of cases of cutaneous, mucocutaneous and mucosal leishmaniasis diagnosed, by country of travel or migration.
Figure 4. The combined number of cases of cutaneous, mucocutaneous and mucosal leishmaniasis diagnosed, by country of travel or migration.
Pathogens 11 00921 g004
Pathogens 11 00921 g005a 550Pathogens 11 00921 g005b 550
Figure 5. The number and percentage of identifications of species/complex by country in: (a) Old World; (b) New World.
Figure 5. The number and percentage of identifications of species/complex by country in: (a) Old World; (b) New World.
Pathogens 11 00921 g005aPathogens 11 00921 g005b
Pathogens 11 00921 g006 550
Figure 6. The proposed algorithm for the approach and management of CL/MCL/ML in non-endemic settings.
Figure 6. The proposed algorithm for the approach and management of CL/MCL/ML in non-endemic settings.
Pathogens 11 00921 g006
Table
Table 1. The epidemiological aspects of imported human leishmaniasis cases between 2000 and 2021.
Table 1. The epidemiological aspects of imported human leishmaniasis cases between 2000 and 2021.
DescriptionVLCL/MCL/ML
FrequencyReferencesFrequencyReferences
Sex
  Male72.2% (164/227)[8,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68]58.2 (3820/6569)[7,8,14,15,20,28,30,38,45,61,65,66,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,158,159,160,161,162,163,164,165,166,167,168,169,170,171,172,173,174,175,176,177,178,179,180,181,182,183,184,185,186,187,188,189,190,191,192,193,194,195,196,197]
  Female27.8% (63/227)[8,20,26,30,31,32,44,45,65,66,67,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,213,214,215,216,217,218,219]41.8% (2749/6569)[8,9,20,28,30,45,61,65,72,73,75,77,81,82,85,87,90,91,95,100,101,112,115,116,118,126,132,133,134,136,139,148,152,158,164,166,169,172,173,175,178,185,188,191,192,195,220,221,222,223,224,225,226,227,228,229,230,231,232,233,234,235,236,237,238,239,240,241,242,243,244,245,246,247,248]
Median age (range)34.5 year (4 months to 86 years)[16,17,18,19,20,22,23,24,25,28,29,30,31,32,33,34,35,36,37,38,39,40,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,62,63,64,66,68,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,214,215,216,217,218,219,249,250,251,252,253]31.0 year (9 months to 86 years)[8,14,15,20,28,30,38,45,61,65,69,70,71,72,73,74,75,76,77,78,79,80,82,83,84,85,86,87,88,89,92,93,94,95,97,98,99,100,102,104,105,106,107,108,110,111,113,114,115,116,117,119,120,121,122,123,124,126,127,128,129,130,131,132,134,135,136,137,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,158,159,161,162,163,164,165,166,167,168,169,170,171,173,174,175,176,177,178,179,180,181,182,183,184,185,186,187,188,189,190,191,193,194,195,196,197,220,221,222,223,224,225,226,227,228,229,230,232,233,234,235,236,237,238,239,241,242,243,244,245,246,247,254,255]
Activity
  Traveler85.2% (294/345) a[8,10,12,17,18,19,20,21,22,23,24,27,28,30,31,32,33,34,35,37,38,39,40,43,45,46,47,48,49,50,51,52,54,56,57,58,59,62,63,64,67,68,79,198,200,201,202,203,204,206,207,208,209,210,211,212,213,215,216,217,218,219,249,250,251,252,256,257,258,259,260,261,262]32.5% (2338/7184) b[7,8,9,10,12,14,15,20,28,30,38,45,65,69,70,71,72,73,74,76,77,78,79,80,81,82,83,84,87,88,89,91,92,96,97,98,100,102,103,104,105,106,108,109,110,111,112,114,118,119,120,121,122,123,124,125,128,129,131,132,133,134,135,137,140,141,142,143,144,145,147,148,150,151,152,153,155,158,159,160,161,162,163,164,165,166,170,171,173,174,175,176,177,178,179,180,181,182,183,184,185,186,189,190,191,192,194,196,221,222,223,226,228,229,230,231,232,233,234,235,236,237,238,239,240,241,243,247,248,254,255,260,263,264,265,266,267,268,269,270,271,272,273]
  Migrant/refugee14.8% (50/345)[7,8,16,17,20,25,28,29,30,44,55,60,208,214,216,261]67.5% (4846/7184) c[8,9,15,20,28,30,45,85,91,95,101,108,115,117,130,132,138,139,149,154,157,158,168,172,181,187,188,193,195,197,220,242,244,246,274,275,276]
Region of infection
Europe61.2% (230/376)[8,10,11,12,17,20,22,23,24,25,26,27,28,31,32,33,34,36,37,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,56,57,58,59,60,62,63,64,65,66,67,189,200,201,202,203,206,207,208,209,210,211,212,214,216,217,218,219,239,249,250,251,252,256,257,258,260,261,272]2.6% (252/9619)[8,10,11,15,20,26,28,45,61,65,66,87,104,109,111,112,124,126,130,132,133,135,143,152,155,156,158,162,190,191,192,207,217,220,222,227,228,230,240,249,263,264,268]
  South Asia and East Asia14.9% (56/376)[10,19,20,21,259,261]4.0% (383/9619)[5,7,8,10,11,12,19,27,29,44,64,83,88,92,110,113,130,134,135,141,165,181,183,187,188,220,226,242,270,272,275,277,278]
  Sub-Saharan Africa9.8% (37/376)[8,10,16,17,20,28,29,45,259]2.2% (214/9619)[8,9,10,11,12,15,20,30,61,81,95,99,119,123,133,136,148,185,192,234,247,254,272,273,277]
  Middle East9.0% (34/376)[8,18,19,20,67]64.3% (6189/9619)[7,9,10,11,12,15,20,45,61,65,81,87,95,103,126,133,145,152,156,157,160,167,169,173,174,175,176,180,181,183,188,191,192,195,230,238,239,240,243,246,268,273,274,275,277,279]
  Latin America and Caribbean1.9% (7/376)[10,55,57,65,199,204,253]18.3% (1759/9619) d[7,8,9,10,11,12,14,15,20,28,30,61,65,69,70,71,72,73,74,75,76,77,78,79,80,81,82,84,87,88,89,90,91,92,93,96,97,98,100,101,102,105,106,107,108,110,116,118,120,121,122,126,128,129,131,132,133,136,139,140,141,142,143,147,149,150,151,154,159,162,163,165,166,167,170,173,175,177,178,179,180,182,184,185,186,189,190,191,193,194,197,221,223,224,228,236,237,241,263,264,266,267,269,270,272,273,276,277,280,281,282]
  North Africa1.9% (7/376)[20,67,246]5.6% (535/9619)[6,8,9,10,11,12,15,20,30,61,81,83,95,132,136,137,148,161,164,169,175,192,230,231,255,268,272,273]
  Central Asia1.3% (5/376)[44,61,67,205,215]0.3% (26/9619)[8,15,20,86,134,185,244,271,275,277]
Region of diagnosis, n (%)
  America1.5% (8/540)[21,43,49,51,55,60,215]6.8% (662/9771) e[72,73,78,80,84,88,92,93,101,110,114,117,120,122,123,127,128,139,141,142,149,150,157,159,163,166,168,175,176,178,180,182,197,221,224,228,234,235,237,238,239,243,244,247,248,266,270,276,280,281]
  Africa3.1% (17/540)[16]NRNA
  Europe80.4% (434/540)[6,8,10,11,12,17,18,20,22,23,24,25,26,27,29,30,32,33,34,35,37,38,39,40,42,44,46,47,48,50,52,53,54,56,58,59,61,62,63,65,66,67,68,69,198,201,202,203,204,205,206,207,208,209,210,212,213,214,216,217,218,219,249,250,252,256,257,258,260,261,262,272]33.1% (3235/9771)[6,7,8,10,11,12,13,14,15,20,25,30,38,61,65,65,70,71,74,76,77,79,81,82,83,86,87,89,90,91,94,95,97,99,102,104,105,106,107,108,109,111,112,113,116,119,121,124,125,126,129,130,131,132,133,134,135,136,137,138,140,143,147,148,151,152,153,154,155,158,161,162,164,165,169,170,171,177,179,181,185,189,190,191,192,193,194,220,222,223,225,226,227,229,231,232,233,240,241,242,245,246,254,255,260,263,264,267,269,272,273,277,282]
  Asia and Oceania15.0% (81/540)[19,28,36,45,57,64,211,251,259]60.1% (5874/9771) f[28,45,69,75,85,88,100,102,115,118,144,145,146,156,160,167,172,173,174,183,184,186,187,188,195,196,230,264,268,271,274,275,278]
a Including military (n = 3); b Including military (n = 1027); c Refugees (n = 4616); migrants (n = 186); refugee or migrant (unspecified, n = 44); d From South America (n = 1126); from Central America (n = 392); unspecified (n = 241); e North America (n = 612); Latin America and Caribbean (n = 50); f In the Middle East (n = 5762); in East Asia and Pacific (n = 105); in South Asia (n = 7); Abbreviations: VL, visceral leishmaniasis; CL, cutaneous leishmaniasis; MCL, mucocutaneous leishmaniasis; ML, mucosal leishmaniasis; NR, not reported.
Table
Table 2. A clinical presentation of visceral leishmaniasis cases.
Table 2. A clinical presentation of visceral leishmaniasis cases.
DescriptionFrequencyReferences
Clinical signs
Fever92.5% (172/186)[16,17,18,19,20,21,22,23,25,27,29,30,31,32,33,36,38,40,43,44,46,47,48,49,50,51,52,53,54,56,57,59,60,62,63,64,66,68,199,200,202,203,207,208,209,210,211,212,214,215,216,218,219,249,250,251,252,256,258,259,260]
Hepatosplenomegaly82.3% (153/186)[16,17,18,19,20,21,22,23,25,27,29,30,31,32,33,36,38,40,43,44,46,47,48,49,50,51,52,53,54,56,57,59,60,62,63,64,66,68,199,200,202,203,207,208,209,210,211,212,214,215,216,218,219,249,250,251,252,256,258,259,260]
Constitutional signs42.5% (79/186)[35,48,55,217,252,259]
Gastrointestinal signs15.6% (29/186)[19,32,35,48,55,56,204,217,251,256,259]
Respiratory signs18.3% (34/186)[19,31,34,46,50,203,211,251,259]
Skin and mucosal haemorrhage12.4% (23/186)[35,48,55,217,252,259]
Lymphadenopathy10.2% (19/186)[35,37,38,56,59,198,205,213,250,256,259]
Skin lesions4.8% (9/186)[19,31,35,40,55,66,204,252,257]
Genitourinary signs1.6% (3/186)[19,29,64]
Edema1.1% (2/186)[35,218]
Ocular lesions0.5% (1/186)[35]
Laboratory findings
Pancytopenia64.0% (80/125)[17,20,21,22,23,24,25,27,30,31,32,33,35,36,38,40,42,43,46,47,49,50,51,52,53,54,56,57,58,59,60,62,63,66,68,200,201,202,203,206,209,210,212,214,215,216,217,218,219,249,250,251,256,258]
Bicytopenia23.2% (29/125) a[17,20,29,44,55,59,64,199,205,253]
Monocytopenia10.4% (13/125) b[19,20,31,44,48,204,207,216,252]
Elevated liver enzymes16.0% (20/125)[19,21,22,32,36,43,48,50,51,59,62,64,202,203,212]
Hyperglobulinemia11.2% (14/125)[21,22,25,32,59,199,201,216,250,251,256]
Hypoalbuminemia6.4% (8/125)[21,22,29,46,201,204,210]
Renal failure1.6% (2/125)[39,48]
Others20.0% (25/125) c[17,26,44,49,50,59,68,206,214,218]
a Leukopenia + anemia (n = 13); anemia + thrombocytopenia (n = 13); b Anemia (n = 10); leukopenia (n = 1); thrombocytopenia (n = 2); c Hemophagocytic lymphohistiocytosis (n = 22); leucocytosis (n = 2); secondary myelofibrosis (n = 1).
Table
Table 4. The therapeutic aspects of visceral leishmaniasis cases.
Table 4. The therapeutic aspects of visceral leishmaniasis cases.
Treatment StrategyFrequency of Total CasesFrequency of Failure/Relapse CasesReferences
Systemic100% (256/256)13.7% (35/256)
Amphotericin B74.8% (184/246)12.0% (22/184)[17,20,21,22,198,200,249,250,251]
Pentavalent antimonials22.0% (54/246)18.5% (10/54)[8,16,18,19,32,40,44,216,256,257,260,261]
Miltefosine0.8% (2/246)50.0% (1/2)[8,58]
Pentamidine0.8% (2/246)50.0% (1/2)[17,257]
Paromomycin0.8% (2/246)50.0% (1/2)[257]
Combination0.8% (2/246) aNR[36,50]
LocalNRNANA
NoneNRNANA
a Liposomal amphotericin B + miltefosine (n = 2); Abbreviations: NA, not applicable; NR, not reported.
Table
Table 5. The clinical presentation of cutaneous New World and Old World leishmaniasis cases—global and by infecting species/complex.
Table 5. The clinical presentation of cutaneous New World and Old World leishmaniasis cases—global and by infecting species/complex.
Clinical SignsNew World Old World
Total CasesReferencesL. braziliensis ComplexReferencesL. guyanensis ComplexReferencesL. mexicana ComplexReferencesTotal CasesReferencesL. donovani ComplexReferencesL. majorReferencesL. tropicaReferences
Number of lesions
  Single79.0% (290/367)[9,15,29,69,70,72,73,75,77,79,82,87,88,92,96,98,100,101,106,116,121,122,128,129,131,139,150,151,158,165,166,167,173,175,179,182,185,186,189,193,194,197,221,223,263,266]58.8% (57/97)[15,28,75,78,87,98,100,116,121,129,166,167,173,175,181,221,223,265]44.0% (22/50)[9,15,73,117,139,151,179,182,266]76.9% (10/13)[15,87,92,122,129,151,186,189,194]58.8% (321/546)[9,15,30,61,66,85,87,95,115,119,132,137,138,143,144,152,153,162,167,169,171,175,185,196,220,222,225,227,232,240,242,246,247,255,260,273,275]67.3% (33/49)[15,87,95,116,133,137,143,144,153,162,227,229,231,235,265]23.2% (26/112)[9,15,30,94,169,171,185,240,255,273]46.0% (23/50)[9,15,87,95,139,167,175,246,275]
  Multiple21.0% (77/367)[9,15,30,71,72,74,75,77,79,82,84,89,93,96,97,100,105,106,110,116,120,129,139,140,142,146,149,159,162,163,166,170,173,179,184,185,191,224,236,237,241,273]41.2% (40/97)[9,15,30,75,79,89,97,100,105,116,129,142,146,162,170,173,273]56.0% (28/50)[9,15,74,93,110,117,120,139,149,159,163,178,236,241]23.1% (3/13)[15,163]41.2% (225/546)[15,30,61,83,85,86,94,95,99,103,104,113,115,123,132,134,145,153,157,164,168,169,174,175,176,181,183,185,187,226,230,231,234,238,239,240,243,254,260,268,273,275]32.7% (16/49)[15,95,132,235]76.8% (86/112)[15,83,95,123,134,156,174,175,238,239,240,243,268,273]54.0% (27/50) [15,95,104,145,157,164,168,169,176,181,187,226,234]
Location of lesions
  Upper limbs41.2% (142/345)[15,30,45,71,72,77,82,89,93,96,97,98,100,105,110,116,120,126,129,139,141,149,150,165,166,173,175,179,182,184,185,191,193,197,221,228,241,263,266]39.5% (34/86)[15,30,45,89,97,98,100,105,116,129,141,166,173,175,221,228,263]47.9% (23/48)[15,73,93,110,117,120,126,139,149,163,178,182,241,266]25.0% (4/16)[15,45,150,166]34.9% (531/1522)[15,30,45,83,85,99,104,115,123,126,127,132,134,145,157,162,164,169,171,172,174,176,183,184,186,195,220,230,231,234,235,238,240,243,244,246,248,254,274,275]31.3% (15/48)[15,126,132,162,235]51.2% (42/82)[15,45,83,123,126,134,171,174,185,238,240,243]47.1% (32/68)[15,45,104,127,145,157,164,169,176,182,234,244,246]
  Lower limbs34.5% (119/345)[15,30,45,69,70,72,73,74,77,82,84,87,106,116,120,121,126,129,139,140,146,151,159,163,166,167,170,173,185,191,224,228,236]44.2% (38/86)[15,30,45,116,120,129,166,167,170,173,228]35.4% (17/48)[15,73,74,117,120,139,151,159,163,236]18.8% (3/16)[15,87,163]17.7% (270/1522)[15,30,45,83,85,94,104,113,115,123,126,134,156,164,169,172,175,183,185,187,195,231,238,239,240,243,248,255,274,275]22.9% (11/48)[15,45,126]40.2% (33/82)[15,30,45,83,123,126,134,156,169,175,238,239,240,243,255]20.6% (14/68)[15,45,104,164,169,187]
  Head and/or neck28.1% (97/345)[15,45,72,74,77,82,87,88,92,93,96,97,100,106,107,108,116,120,122,126,128,129,131,139,140,142,146,147,159,162,166,173,177,184,186,189,194,223,228,241]20.9% (18/86)[15,45,87,97,100,107,116,129,142,146,162,173,177,223,228]33.3% (16/48)[15,73,74,93,117,120,126,139,159,241,266]56.3% (9/16)[15,92,122,128,147,186,189,194]50.6% (770/1522)[15,45,85,86,87,113,115,119,123,126,132,134,137,139,143,144,145,152,153,157,164,167,168,172,175,183,184,185,195,206,220,222,225,226,227,230,232,235,240,242,244,245,246,248,274,275]45.8% (22/48)[15,87,132,137,143,144,153,181,196,225,227,229,232,235,245]18.3% (15/82)[15,123,126,134,240]44.1% (30/68)[15,45,87,139,145,157,164,167,168,175,181,226,244,246]
  Trunk8.1% (28/345)[15,30,45,82,116,120,166,173,179,185,190,228]5.8% (5/86)[15,116,166,173,228]6.3% (3/48)[15,120,178]6.3% (1/16)[45]2.0% (30/1522)[15,45,85,123,132,134,149,164,171,172,185,195,231,240,243,244,247,248]6.2% (3/48)[15,132]9.8% (8/82)[15,45,134,149,240]5.9% (4/68)[164,244]
Type of lesions
  Ulcer77.2% (271/351)[15,30,61,69,70,71,72,73,77,78,79,82,84,87,88,89,93,96,97,98,101,105,106,107,108,110,116,120,122,127,129,132,139,140,147,151,159,165,166,167,170,175,179,185,191,194,197,223,236,237,241,245,263]84.1% (65/77)[15,30,78,79,87,97,98,105,107,116,121,129,167,170,175,223,263]77.8% (35/45)[15,73,93,110,117,120,139,151,159,178,236,241]53.8% (7/13)[122,128,166,178]56.1% (270/481)[15,30,61,83,85,94,99,103,104,113,122,127,132,134,143,145,156,160,162,164,168,169,171,174,176,182,183,185,187,231,234,235,238,239,240,242,243,244,245,246,248,254,255]40.9% (18/44)[15,116,132,143,162,235,245]71.8% (61/85)[15,30,83,123,134,156,171,174,185,238,239,240,243,255]51.1% (24/47)[15,104,127,145,164,167,168,169,176,181,187,234,244,246]
  Lymphadenopathy30.5% (128/420)[15,75,77,79,82,97,100,105,108,110,121,125,129,142,147,159,165,166,177,178,228]16.5% (15/91)[75,79,97,100,105,121,129,142,177,228]12.8% (6/47)[110,117,159,179]NRNA1.2% (21/1707)[15,153,159,163,224,271]3.4% (2/58)[162,229]NRNA1.4% (1/71)[234]
  Plaque/macular/crust14.8% (52/351)[15,61,82,106,107,116,120,131,141,142,150,159,162,163,179,197,241]9.1% (7/77)[15,107,116,141,142,162,166]8.9% (4/45)[15,120,159,178,241]23.1% (3/13)[15,150]20.2% (97/481)[15,85,115,132,134,137,152,153,157,164,168,169,175,196,227,235,240,244]31.8% (14/44)[15,132,137,153,196,227,235]12.9% (11/85)[15,134,169,240]34.0% (16/47)[15,157,164,168,169,175,244]
  Papule/nodule10.0% (35/351)[15,82,84,92,93,109,116,139,140,149,162,163,179,183,184,185,193,221,224,266]9.1% (7/77)[116,162,221]17.8% (8/45)[15,93,110,139,149,163,182,266]15.4% (2/13)[15,93]24.9% (120/481)[15,30,83,86,87,104,119,132,134,144,145,152,169,171,172,174,175,185,187,190,220,222,225,226,234,245,246,247,268]29.5% (13/44)[15,87,132,144,190,225,229,232,245]18.8% (16/85)[15,134,171,174,175]36.2% (17/47)[15,88,104,145,169,187,226,234,246]
  Other1.7% (6/351)[15,74,87]1.3% (1/77)[15]NRNA7.7% (1/13)[87]1.5% (7/481)[15]NRNANRNA2.1% (1/47)[15]
Atypical presentations
  Disseminated0.1% (2/1759)[14,182]NRNA0.7% (2/282)[15,192]NRNA0.06% (5/7860)[10,15,235,260]1.4% (4/280)[10,15,235,260]0.1% (1/923)[192]NRNA
  PKDL0.1% (1/1759)[15]NRNANRNANRNA0.04% (3/7860)[11,15,28]0.7% (2/280)[11,27]NRNANRNA
Abbreviations: PKDL, Post Kala-azar dermal leishmaniasis; NA, not applicable; NR, not reported.
Table
Table 6. Therapeutic aspects of cutaneous Old World leishmaniasis cases—global and by infecting species/complex.
Table 6. Therapeutic aspects of cutaneous Old World leishmaniasis cases—global and by infecting species/complex.
Treatment StrategyTotal Cases L. donovani Complex L. major L. tropica
Frequency of CasesFrequency of Failure/Relapse CasesReferencesFrequency of CasesFrequency of Failure/Relapse CasesReferencesFrequency of CasesFrequency of Failure/Relapse CasesReferencesFrequency of CasesFrequency of Failure/Relapse CasesReferences
Systemic55.7% (282/506)20.2% (57/282) 53.4% (47/88)17.0% (8/47) 76.3% (87/114)19.5% (17/87) 58.5% (24/41)12.5% (3/24)
  Azole28.7% (81/282)40.7% (33/81)[15,85,86,95,115,126,127,133,134,152,153,169,185,230,235,246]10.6% (5/47)100% (5/5)[158,166,187]31.0% (27/87)33.3% (9/27)[95,116,169]37.5% (9/24)22.2% (2/9)[122,160,166,207,219,222]
  Miltefosine29.8% (84/282)935% (8/84)[15,112,132,133,155,158,160,162,180,183,232,240,255,260]31.9% (15/47)6.7% (1/15)[132,133,162,229,232,255]42.5% (37/87)10.8% (4/37)[128,240,255]NRNANA
  Amphotericin B24.5% (69/282)23.2% (16/69)[18,20,28,111,114,119,126,130,132,133,135,160,164,168,187,190,196,244,245,260]42.5% (20/47)10.0% (2/20)[20,28,66,111,130,132,133,135,190,192,196,245]11.5% (10/87)40.0% (4/10)[28,126,161,192]62.5% (15/24)6.7% (1/15)[28,164,168,187,192,244]
  Antimonials (intramuscular)13.8% (39/282)NR[15,94,109,132,133,143,156,230,233]10.6% (5/47)NR[109,132,133,143,233]2.3% (2/87)NR[133,156]NRNANA
  Combination1.8% (5/282) aNR[30,174,185]NRNRNA4.6% (4/87) bNR[174,185]NRNANA
  Pentamidine1.4% (4/282)NR[20]2.1% (1/47)NR[20]8.0% (7/87)NR[81,135]NRNANA
Local34.0% (172/506)7.0% (12/172) 25.0% (22/88)9.1% (2/22) 20.2% (23/114)8.7% (2/23) 36.6% (15/41)26.7% (4/15)
  Antimonials (intralesional)50.6% (87/172)8.0% (7/87)[15,20,30,83,85,87,132,133,144,145,164,167,172,176,231,246,260]36.4% (8/22)NR[20,87,132,144]8.7% (2/23)50% (1/2)[30,83]46.7% (7/15)42.9% (3/7)[133,145,164,167,176,246]
  Paromomycin20.3% (35/172)8.6% (3/35)[15,20,104,124,133,226,227,239,243,260]22.7% (5/22)20.0% (1/5)[124,133,227]69.6% (16/23)NR[166,190,202]40.0% (6/15)16.7% (1/6)[20,104,133,226]
  Combination18.6% (32/172) c6.3% (2/32)[15,123]NRNANA4.3% (1/23) d100% (1/1)[123]NRNANA
  Cryotherapy, thermotherapy, excision10.5% (18/172)NR[15,126,133,138,157,242,260]40.9% (9/22)11.1% (1/9)[126,133,182]17.4% (4/23)NR[126,133]13.3% (2/15)NR[138,157]
None9.5% (48/506)8.3% (4/65)[15,20,87,115,126,171,240,247,260]21.6% (19/88)NR[20,126,260]2.6% (3/114)NR[126,171,240]2.4% (1/41)NR[87]
Systemic + local0.8% (4/506) e [126,133,238]NRNANA0.9% (1/114) f100% (1/1)[238]2.4% (1/41) gNR[133]
a Liposomal amphotericin B + miltefosine (n = 2); intramuscular pentavalent antimonial + ketoconazole (n = 3); b Liposomal amphotericin B + miltefosine (n = 1); intramuscular pentavalent antimonial + ketoconazole (n = 3); c Cryotherapy + intralesional pentavalent antimonial (n = 32); d Cryotherapy + intralesional pentavalent antimonial (n = 1); e Liposomal amphotericin B + intralesional pentavalent antimonial (n = 1); fluconazole + paromomycin + cryotherapy (n = 1); fluconazole + paromomycin (n = 1); itraconazole + cryotherapy (n = 1); f Fluconazole + paromomycin (n = 1); g Itraconazole + cryotherapy (n = 1); Abbreviations: NA, not applicable; NR, not reported.
Table
Table 7. Therapeutic aspects of cutaneous New World leishmaniasis cases—global and by infecting species/complex.
Table 7. Therapeutic aspects of cutaneous New World leishmaniasis cases—global and by infecting species/complex.
Treatment StrategyTotal CasesL. braziliensis Complex L. Guyanensis Complex L. mexicana Complex
Frequency of CasesFrequency of Failure/Relapse CasesReferencesFrequency of CasesFrequency of Failure/Relapse CasesReferencesFrequency of CasesFrequency of Failure/Relapse CasesReferencesFrequency of CasesFrequency of Failure/Relapse CasesReferences
Systemic86.4% (521/603)12.5% (52/521) 88.8% (199/224)12.7% (25/199) 85.1% (40/47)25.0% (10/47) 60.0% (9/15)33.3% (3/9)
  Antimonials (intramuscular)53.7% (280/521)7.1% (20/280)[15,20,30,69,71,72,73,75,76,77,78,79,80,82,87,89,92,100,101,105,107,108,116,120,125,133,142,165,166,173,223,263,266,269]40.1% (81/199)8.6% (7/81)[30,75,76,79,87,89,100,105,107,116,133,142,166,173,221,223,263]22.5% (9/40)NR[73,120,133,266]11.1% (1/9)100% (1/1)[92]
  Amphotericin B28.4% (148/521)16.9% (25/148)[15,28,61,77,98,100,116,120,121,128,139,149,154,159,163,166,167,170,173,177,194,224,237]52.3% (104/199)14.8% (12/81)[20,28,98,116,121,133,167,170,173,177]35.0% (14/40)42.9% (6/14)[117,120,139,149,159,163]66.7% (6/9)33.3% (2/6)[28,128,166,194]
  Pentamidine10.4% (26/521) 11.5% (3/26)[15,61,96,133,151,241]0.5 (1/199)NR[133]17.5% (7/40)NR[133,151,241]NRNANA
  Miltefosine8.4% (44/521)34.1% (15/44)[15,93,116,126,129,133,140,162,173,178,180,228]6.0% (12/199)41.7% (5/12)[116,129,162,173,180,228]15.0% (6/40)33.3% (2/6)[93,126,133,178]NRNANA
  Azole2.1% (11/521)9.1% (1/11)[15,20,30,61,74,88,97,133]0.5% (1/199)100% (1/1)[97]10.0% (4/40)50.0% (2/4)[74,133]11.1% (1/9)NR[20]
  Combination2.3% (12/521) a8.3% (1/12)[15,30,84,102,132,179,185,186]NRNANANRNANA11.1% (1/9) bNR[186]
Local7.0% (42/603)4.7% (2/42) 0.4% (1/224)100% (1/1) 6.4% (3/47)NR 6.7% (1/15)NR
  Antimonials (intralesional)45.2% (19/42)5.3% (1/19)[15,30,61,87,133,146,236,269]NRNANA66.7% (2/3)NR[133,236]100% (1/1)NR[87]
  Combination23.8% (10/42)NR[125,132]NRNANANRNANANRNANA
  Paromomycin11.9% (5/42)20.0% (1/5)[15,133]100% (1/1)100% (1/1)[133]NRNANANRNANA
  Cryotherapy, thermotherapy, excision9.1% (8/42)NR[110,185,191,193,269]NRNANA33.3% (1/3)NR[110]NRNANA
None5.6% (34/603)2.9% (1/34)[15,106,110,122,126,133,150,173,189]9.8% (22/224)NR[173]NRNANA26.7% (4/15)25.0% (1/4)[122,133,150,189]
  Systemic + local1.0% (6/603) c33.3% (2/6)[30,61,96,146,147,182,184]0.9% (2/224)NR[30,146]2.1% (1/47)NR[182]6.7% (1/15)NR[147]
a Liposomal amphotericin B + miltefosine (n = 3); pentamidine + ketoconazole (n = 1); miltefosine + ketoconazole (n = 1); b Liposomal amphotericin B + azole (n = 1); c Cryotherapy + intralesional pentavalent antimonial (n = 8); excision + intralesional pentavalent antimonial (n = 2); Abbreviations: NA, not applicable; NR, not reported.
Table
Table 8. The clinical aspects of mucocutaneous and mucosal leishmaniasis cases.
Table 8. The clinical aspects of mucocutaneous and mucosal leishmaniasis cases.
DescriptionFrequency in MCLReferencesFrequency in MLReferences
Sex
  Male 74.6% (47/63)[14,30,38,65,74,77,80,82,102,107,108,142,146,153,173,177,179,180]78.8% (26/33)[30,76,109,111,114,130,132,135,154,155,158,161,173,180,190]
  Female25.4% (16/63)[20,65,82,173,223,228,245]21.2% (7/33)[20,30,158,233]
Median age (range)37 years (17 to 75 years)[9,11,14,20,30,38,65,74,77,80,82,102,107,108,142,146,173,177,179,180,223,228,272]64 years (24 to 84 years)[20,30,76,82,109,111,114,130,132,135,154,155,158,161,173,180,190,233]
Region of infection
  New World80.6% (58/72)[9,11,12,20,30,65,74,77,80,82,102,107,108,142,146,173,177,179,180,223,228,272]23.1% (9/39)[30,76,82,133,154,173]
   South America89.5% (51/57)[9,11,12,20,30,65,77,80,82,102,107,108,142,146,173,177,179,180,228,272]87.5% (7/8)[30,76,82,154,173]
   Central America10.5% (6/57)[14,74,82,223]12.5% (1/8)[154]
  Old World19.4% (14/72)[6,11,153,245]76.9% (30/39)[20,26,30,109,111,114,130,132,133,135,158,161,180,190,233,273]
   Europe and Central Asia85.7% (12/14)[11,153,245]85.7% (24/28)[20,26,109,111,130,132,133,135,158,190,233,273]
   Subsaharan Africa7.1% (1/14)[11]NRNA
    South Asia7.1% (1/14)[6]3.6% (1/28)[30]
    Middle EastNRNA7.1% (2/28)[114,180]
    North AfricaNRNA3.6% (1/28)[161]
Species/complex
  L. braziliensis complex67.3% (33/49)[12,20,30,102,107,129,142,146,173,223,228]20.0% (6/30)[30,76,133,173]
  L. (Viannia) sp.16.3% (8/49)[38,77,82]3.3% (1/30)[82]
  L. donovani complex12.2% (6/49)[153,245]70.0% (21/30)[20,26,109,111,130,132,133,135,158,190,233,273]
  L. guyanensis complex4.1% (2/49)[74]NRNA
   L. majorNRNA3.3% (1/30)[161]
   L. tropicaNRNA3.3% (1/30)[180]
Mucosal location
Nasal only68.4% (26/38)[30,38,74,77,80,82,102,107,142,173,177,179,223,245]37.0% (10/27)[30,76,132,133,154,158,161,180]
Oral and nasal15.8% (6/38)[108,146,173]NRNA
  Oral only12.2% (2/38)[129,173]29.6% (8/27) a[111,114,133,135,173,190,233]
  Pharyngeal7.9% (3/38)[82,180,228]NRNA
  Laryngeal2.6% (1/38)[30]29.6% (8/27)[30,82,109,130,155,158]
Mucosal signs/symptoms
  Nasal obstruction57.9% (22/38)[38,74,82,102,107,108,173]21.1% (4/19)[154,158,180]
  Nasal discharge34.2% (13/38)[38,74,82,102,107,108,173]15.8% (3/19)[76]
  Localized edema18.4% (7/38)[77,80,82,102,107,223]36.8% (7/)[26,76,109,111,114,159]
  Epistaxis10.5% (4/38)[38,107]10.5% (2/19)[154,161]
  Palate perforation7.9% (3/38)[108,146]10.5% (2/19)[154,233]
  Odynophagia7.9% (3/38)[82,180,228]5.3% (1/19)[82]
  Cough2.6% (1/38)[179]5.3% (1/19)[158]
  Dysphagia2.6% (1/38)[179]10.5% (2/19)[111,130]
  Hoarseness2.6% (1/38)[179]42.1% (8/19)[30,82,109,130,155,158]
  Nasal septum perforation2.6% (1/38)[107]10.5% (2/19)[154,161]
Lymphadenopathy/lymphangitis11.1% (10/90)[38,82,108,129,142,177,228]2.6% (1/19)[158]
a Including in the tongue (n = 4); Abbreviations: MCL, mucocutaneous leishmaniasis; ML, mucosal leishmaniasis; NA, not available; NR, not reported.
Table
Table 9. The types of immunosuppression and therapeutic outcomes of immunosuppressed patients with leishmaniasis.
Table 9. The types of immunosuppression and therapeutic outcomes of immunosuppressed patients with leishmaniasis.
DescriptionFrequency in VLReferencesFrequency in CLReferencesFrequency in MCLReferencesFrequency in MLReferences
Cases21.7% (117/540)[8,10,20,24,26,27,28,32,34,35,36,38,39,40,42,47,48,54,55,57,58,61,66,68,202,203,204,205,207,208,209,217,250,252,257,258,260,261]0.7% (70/9642)[8,15,20,28,30,66,119,126,132,133,192,224,260,277]12.2% (11/90)[8,15,26,153,192,245]41.0% (16/39)[15,20,30,132,135,158,190]
Immunosuppressive condition
  HIV49.1% (56/114)[8,10,20,26,28,32,35,36,47,55,61,66,68,205,250,257,261]14.8% (8/54)[28,30,260,277]44.4% (4/9)[8,192]9.1% (1/11)[135]
  Therapy25.4% (29/114) 44.4% (24/54) 33.3% (3/9) 72.7% (8/11)
   Methotrexate (±steroid)34.5% (10/29)[20,40,54,66,208,260,261]4.2% (1/24)[20]NRNA12.5% (1/8)[158]
   Steroid only 24.1% (7/29)[26,34,54,202,252,260,261]NRNANRNA50.0% (4/8)[30,158]
   Anti-TNFα (±other drugs)20.7% (6/29) a[66,209,261]58.3% (14/24) b[119,132]33.3% (1/3) c[245]25.0% (2/8) d[165,194]
   Azatioprine (±steroid)10.3% (3/29)[27,48,261]4.2% (1/24)[126]NR NANRNA
   Unspecified6.9% (2/29)[10]33.3% (8/24)[66,192]66.7% (2/3)[192]12.5% (1/8)[20]
   Other monoclonal antibody3.4% (1/29) e[57]NRNANRNANRNA
  Malignancy12.3% (14/114) f[20,26,39,58,61,66,203,217,257,258,261]NRNA11.1% (1/9) g[26,153]18.2% (2/11) h[158,190]
  Diabetes mellitus10.5% (12/114)[25,26,38,42,181,202,204,207,261]38.9% (21/54)[129,277]11.1% (1/9)[179]NRNA
  Transplant2.6% (3/114) i[24,257,260]1.9% (1/54) j[224]NRNANRNA
Region of infection
  Old World98.2% (112/114)[8,10,20,24,26,27,28,32,34,36,38,39,40,42,47,48,54,57,58,61,66,202,203,205,207,208,209,217,250,252,257,258,260,261]91.3% (42/46) l[8,15,20,26,28,30,66,119,126,132,133,135,153,158,190,192,245,260]
  New World1.8% (2/114)[55,204]8.7% (4/46) l[8,15,133,192,224]
Species/complex
  L. donovani complex100% (60/60)[10,20,24,26,27,28,40,47,48,54,57,58,61,66,68,202,204,209,250,260,261]88.9% (24/27) l[20,66,132,135,153,158,190,245,260]
   L. aethiopicaNRNA7.4% (2/27) l[119,132]
  L. braziliensis complexNRNA3.7% (1/27) l[26]
Treatment strategy
  Systemic100% (37/37) k[8,20,24,26,27,32,34,35,36,39,40,47,48,54,55,58,61,66,68,202,203,204,205,208,209,217,250,252,257,260]92.6% (25/27) l[20,30,66,119,126,132,135,153,158,190,192,224,245]
  LocalNRNA7.4% (2/27) l
Relapses21.6% (8/37)[10,32,35,47,55,58,66,252,257,260] 22.2% (6/27) l
a Methotrexate + adalimumab (n = 3); methotrexate + etanercept (n = 1); azathioprine + infliximab (n = 1); methotrexate + unspecified (n = 1); b Etanercept (n = 12); methotrexate + adalimumab (n = 1); unspecified (n = 1); c Methotrexate + adalimumab (n = 1); d Methotrexate + adalimumab (n = 1); unspecified (n = 1); e Fingolimod (n = 1); f Lymphoma (not specified) (n = 3); chronic lymphocytic leukemia (n = 2); thymoma (n = 2); non-Hodgkin lymphoma (n = 1); T-cell lymphoma (n = 1); MALT lymphoma (n = 1); myelofibrosis (n = 1); myeloma (n = 1); breast (n = 1); testicular (n = 1); g Hepatocellular carcinoma (n = 1); h Acute lymphocytic leukemia; 1 non-small cell lung cancer (n = 1); i Kidney (n = 1); kidney + pancreas (n = 1); Allo-HSCT (n = 1); j Kidney (n = 1); k Liposomal amphotericin B (n = 33); 3 intramuscular pentavalent antimonial (n = 3); 1 liposomal amphotericin (n = 1); l CL + MCL + ML; Abbreviations: VL, visceral leishmaniasis; CL, cutaneous leishmaniasis; MCL, mucocutaneous leishmaniasis; ML, mucosal leishmaniasis; TNF, Tumor Necrosis Factor; HSCT, Hematopoietic stem cell transplant; MALT, mucosa-associated lymphoid tissue; NA, not applicable.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Rocha, R.; Pereira, A.; Maia, C. Non-Endemic Leishmaniases Reported Globally in Humans between 2000 and 2021—A Comprehensive Review. Pathogens 2022, 11, 921. https://doi.org/10.3390/pathogens11080921

AMA Style

Rocha R, Pereira A, Maia C. Non-Endemic Leishmaniases Reported Globally in Humans between 2000 and 2021—A Comprehensive Review. Pathogens. 2022; 11(8):921. https://doi.org/10.3390/pathogens11080921

Chicago/Turabian Style

Rocha, Rafael, André Pereira, and Carla Maia. 2022. "Non-Endemic Leishmaniases Reported Globally in Humans between 2000 and 2021—A Comprehensive Review" Pathogens 11, no. 8: 921. https://doi.org/10.3390/pathogens11080921

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop